Data / Research funding / Coronaviruses Therapeutics and Interventions
Coronaviruses Therapeutics and Interventions: 444 NIH awards ($1.8B) to 213 organizations
444 NIH awards ($1.8B) in the NIH spending category Coronaviruses Therapeutics and Interventions, to 213 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
Get awards on Coronaviruses Therapeutics and InterventionsWatch Coronaviruses Therapeutics and Interventions
- Topic
- NIH spending category
Awards
444 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $965,792,899 | June 15, 2020 | June 30, 2026 | THOMAS, SONIA M | reporter.nih.gov |
| AI-driven Structure-enabled Antiviral Platform (ASAP) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $89,845,851 | May 16, 2022 | August 31, 2027 | CHODERA, JOHN DAMON | reporter.nih.gov |
| CLINICAL RESEARCH OPERATIONS AND MANAGEMENT SUPPORT (CROMS) - SARS CoV-2 Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $86,825,316 | April 17, 2017 | April 16, 2024 | HOLMES, MELYNDA | reporter.nih.gov |
| COVID-19: NIAID Regulatory Support Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $63,227,516 | April 15, 2023 | April 14, 2024 | RAFI, ASIMAH | reporter.nih.gov |
| Anti-NMDA Receptor Antibodies in Adult Brain Dysfunction: Lessons from Lupus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,990,990 | August 1, 2008 | June 30, 2030 | DIAMOND, BETTY | reporter.nih.gov |
| Successful Clinical Response In Pneumonia Therapy (SCRIPT) Systems Biology Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,773,513 | January 17, 2018 | December 31, 2027 | WUNDERINK, RICHARD G | reporter.nih.gov |
| Development of an Antiviral to Combat Viral Infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $12,480,276 | November 15, 2022 | April 17, 2025 | CHANG, JINHONG | reporter.nih.gov |
| Trans-omics Integration of Multi-omics Studies for Osteoporosis | NIH | National Institute on Aging | 2021 to 2025 | $12,202,183 | September 15, 2017 | June 30, 2027 | DENG, HONG-WEN | reporter.nih.gov |
| Human anti-viral immune responses in tissues and circulation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,930,741 | January 1, 2017 | February 28, 2027 | FARBER, DONNA L. | reporter.nih.gov |
| Alzheimer's Disease and Related Disorders Treatment and Outcomes in America: Changing Policies and Systems. | NIH | National Institute on Aging | 2021 to 2025 | $11,898,685 | September 15, 2007 | May 31, 2029 | TRIVEDI, AMAL N. | reporter.nih.gov |
| Durable Alteration of the Human Immune system after Infection or Immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,785,761 | June 8, 2009 | May 31, 2029 | CHUNG, RAYMOND T | reporter.nih.gov |
| Clinical Development of COVID-19 Therapeutics | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $11,286,393 | September 22, 2023 | February 15, 2026 | WANG, STANLEY | reporter.nih.gov |
| Administrative Supplement Request for 2025 Systems Biology for Infectious Diseases Annual Meeting | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,511,156 | August 17, 2018 | May 31, 2028 | KROGAN, NEVAN J | reporter.nih.gov |
| Establish a Public Private Partnership for COVID19 Research | NIH | Office of the Director, National Institutes of Health | 2021 to 2023 | $10,186,691 | May 2, 2020 | February 29, 2024 | ADAM, STACEY | reporter.nih.gov |
| Administrative Supplements for NIAID Regional Biocontainment Laboratories (RBL) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $7,369,853 | September 23, 2021 | February 28, 2025 | ALEM, FARHANG | reporter.nih.gov |
| CCC for NHLBI Prevention and Early Treatment of Acute Lung Injury PETAL Network | NIH | National Heart, Lung, and Blood Institute | 2021 | $5,617,232 | June 17, 2014 | October 31, 2023 | THOMPSON, BOYD TAYLOR | reporter.nih.gov |
| Autonomously deploying, co-evolving SARS-CoV-2 antiviral: a new paradigm for pandemic prevention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,817,583 | September 24, 2021 | August 31, 2024 | RODICK, ROBERT | reporter.nih.gov |
| Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,799,861 | September 15, 2020 | August 31, 2025 | DIAMOND, MICHAEL S | reporter.nih.gov |
| PROJECT MANAGEMENT SUPPORT FOR COMMUNITY ENGAGEMENT ON TRANS-NIH THERAPEUTICS AND VACCINE TRIALS | NIH | National Heart, Lung, and Blood Institute | 2021 | $4,297,649 | July 29, 2020 | January 28, 2021 | SHINGLEDECKER, DANIEL | reporter.nih.gov |
| Targeting innate immune pathways, and inflammatory cell death in cytokine-mediated diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,212,442 | June 15, 2021 | May 31, 2026 | KANNEGANTI, THIRUMALA-DEVI | reporter.nih.gov |
| Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation studies to Evaluate the Safety and Efficacy of SPI-1005 in Moderate and Severe COVID-19 Patients | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $4,174,965 | April 6, 2021 | April 5, 2023 | KIL, JONATHAN | reporter.nih.gov |
| Impact of Care Delivery and Therapeutic Changes on Patients with Alzheimer's Disease and Alzheimer's Disease Related Dementias | NIH | National Institute on Aging | 2021 to 2025 | $4,115,749 | September 30, 2021 | May 31, 2027 | HSU, JOHN | reporter.nih.gov |
| Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,828,356 | September 1, 2021 | August 31, 2026 | GLENN, JEFFREY S | reporter.nih.gov |
| Cell competition in pulmonary fibrosis and ARDS | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,796,920 | August 20, 2022 | July 31, 2029 | DE LANGHE, STIJN PIET JOHAN | reporter.nih.gov |
| Mechanism and Inhibition of SARS-CoV-2 Entry | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,776,105 | July 8, 2021 | June 30, 2026 | WHELAN, SEAN PJ | reporter.nih.gov |
| Genetic Investigation of Covid 19 in Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,774,284 | August 1, 2022 | July 31, 2027 | KAHN, MARK L | reporter.nih.gov |
| Advancing the development of a novel class of small molecules for treating pan-coronavirus infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,659,295 | August 10, 2021 | July 31, 2027 | EINAV, SHIRIT | reporter.nih.gov |
| Engineering protease-resistant antiviral peptide inhibitors for SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,639,039 | August 1, 2021 | July 31, 2027 | MOSCONA, ANNE | reporter.nih.gov |
| Fusion inhibitors that block host-to-host transmission of SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,603,355 | August 1, 2021 | July 31, 2027 | POROTTO, MATTEO | reporter.nih.gov |
| De Novo Design of Minibinder Antagonists for COVID-19 and Future Pandemics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,504,899 | August 2, 2021 | July 31, 2026 | BAKER, DAVID | reporter.nih.gov |
| Inhalation Therapy Platform for Coronavirus Infection Treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,373,230 | September 17, 2021 | August 31, 2026 | STAYTON, PATRICK S. | reporter.nih.gov |
| Remotely Monitored, Mobile health-supported High Intensity Interval Training after COVID-19 Critical Illness (REMM HIIT-Covid19) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,292,532 | September 17, 2021 | August 31, 2027 | WISCHMEYER, PAUL E | reporter.nih.gov |
| Hybrid Methods for Dynamic Structure Analysis of Proteins from Pathogenic Microorganisms | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,290,000 | July 1, 2021 | April 30, 2027 | MONTELIONE, GAETANO T | reporter.nih.gov |
| Broad-spectrum therapeutics against SARS-CoV-2 3CL protease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,268,877 | August 19, 2021 | July 31, 2026 | SCHINAZI, RAYMOND FELIX | reporter.nih.gov |
| A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,217,894 | August 4, 2023 | July 31, 2027 | SHOEMAKER, CHARLES BIX | reporter.nih.gov |
| Targeted Gene Delivery Systems Treating Lung Diseases | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,172,072 | June 15, 2022 | May 31, 2026 | TIRRELL, MATTHEW | reporter.nih.gov |
| Development of peptide nucleic acid antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,164,488 | February 10, 2021 | January 31, 2025 | ARYA, DEV PRIYA | reporter.nih.gov |
| Mechanism-based Targeting of the RNA Processing Machinery of SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,161,127 | August 1, 2021 | July 31, 2027 | GUPTA, YOGESH K | reporter.nih.gov |
| Epitope-focused vaccine strategies against Zika virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $3,153,813 | August 1, 2018 | July 31, 2023 | NUSSENZWEIG, MICHEL C | reporter.nih.gov |
| Mechanisms of atherosclerotic cardiovascular complications | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,139,538 | September 1, 2022 | August 31, 2026 | GIANNARELLI, CHIARA | reporter.nih.gov |
| Structure, function, and inhibition of the SARS-CoV-2 replication-transcription complex | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,120,244 | August 6, 2021 | July 31, 2026 | DARST, SETH A. | reporter.nih.gov |
| Mechanisms and pathogenicity of SARS-CoV-2-induced neutrophil extracellular traps | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,116,400 | September 17, 2021 | August 31, 2027 | LOONEY, MARK ROBERTS | reporter.nih.gov |
| Optimizing lipid RVn monophosphate prodrugs to maximize RVn-triphosphate delivery | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,082,513 | July 18, 2025 | June 30, 2029 | CARLIN, AARON F. | reporter.nih.gov |
| Rapid response for pandemics: single cell sequencing and deep learning to predict antibody sequences against an emerging antigen | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,071,572 | September 16, 2021 | August 31, 2025 | RAY, ANIMESH | reporter.nih.gov |
| Elucidation of Assembly and Budding Mechanisms of SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,067,049 | September 19, 2022 | July 31, 2027 | STAHELIN, ROBERT VIRGIL | reporter.nih.gov |
| Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,044,448 | July 9, 2020 | June 30, 2027 | DU, LANYING | reporter.nih.gov |
| Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,999,998 | June 7, 2023 | May 31, 2027 | COBURN, GLEN | reporter.nih.gov |
| Reducing COVID-related PTSD symptoms in Frontline Healthcare Workers through Trauma-Focused Treatment in Employee Assistance Programs | NIH | National Institute of Mental Health | 2022 to 2025 | $2,977,008 | September 1, 2022 | June 30, 2027 | SRIPADA, REBECCA KAUFMAN | reporter.nih.gov |
| Small Molecule Protease Inhibitors against MERS-CoV and Coronaviruses of Pandemic Potential | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,966,398 | July 19, 2024 | May 31, 2029 | CHANG, KYEONG-OK | reporter.nih.gov |
| Low Density Neutrophils Link Inflammation and Coagulopathy in COVID-19 | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,948,542 | September 23, 2022 | August 31, 2026 | YAN, JUN | reporter.nih.gov |
| Mechanisms and Treatment of SARS-CoV-2 induced Lung Endothelial Injury | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,941,237 | February 1, 2022 | January 31, 2027 | REHMAN, JALEES | reporter.nih.gov |
| ACE2 immunodecoys for long-lasting immunoprophylaxis against sarbecovirus and merbecoviruses that target human ACE2 | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,937,578 | August 18, 2025 | July 31, 2029 | LAI, SAMUEL | reporter.nih.gov |
| Targeting abnormal alveolar immune activation and failed epithelial repair in COVID-19 | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,933,325 | April 1, 2022 | March 31, 2026 | MISHARIN, ALEXANDER | reporter.nih.gov |
| Diagnosing and predicting risk in children with SARS-CoV-2- related illness | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 | $2,924,117 | January 1, 2021 | November 30, 2024 | BURNS, JANE C | reporter.nih.gov |
| Clinical analysis and therapeutic development of exosomal ACE2 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,922,951 | July 15, 2022 | June 30, 2027 | LIU, HUIPING | reporter.nih.gov |
| Kinetic and structural basis for SARS-CoV-2 RNA-dependent RNA polymerase specificity and inhibition | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,889,190 | July 16, 2021 | June 30, 2027 | JOHNSON, KENNETH ALLEN | reporter.nih.gov |
| Role of Complement Activation in Severe COVID-19 | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,886,906 | August 20, 2022 | July 31, 2026 | QIN, XUEBIN | reporter.nih.gov |
| VentNet: A Real-Time Multimodal Data Integration Model for Prediction of Respiratory Failure in Patients with COVID-19 | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,865,878 | February 15, 2022 | January 31, 2027 | NEMATI, SHAMIM | reporter.nih.gov |
| Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,853,123 | January 8, 2019 | December 31, 2025 | PLEMPER, RICHARD K. | reporter.nih.gov |
| Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chip | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,824,730 | May 1, 2021 | April 30, 2026 | CONNOR, JOHN H | reporter.nih.gov |
| Broadly neutralizing SARS-CoV-2 peptidic knobs | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,809,275 | June 9, 2023 | May 31, 2028 | SMIDER, VAUGHN VASIL | reporter.nih.gov |
| Telehealth 2.0: Evaluating effectiveness and engagement strategies for asynchronous texting based trauma focused therapy for PTSD | NIH | National Institute of Mental Health | 2021 | $2,792,355 | September 17, 2021 | September 16, 2025 | WILTSEY STIRMAN, SHANNON | reporter.nih.gov |
| COVID-19 Lung Microvascular and Parenchymal Sequelae (Lung-MaPS) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,791,226 | July 15, 2021 | April 30, 2026 | OELSNER, ELIZABETH | reporter.nih.gov |
| Discovery of SARS-CoV-2 antivirals using a replicon assay | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,764,202 | August 1, 2022 | July 31, 2027 | SARAFIANOS, STEFAN G | reporter.nih.gov |
| TMPRSS2 as a potential target for treatments of COVID-19 and respiratory infectious viruses in lung | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,759,863 | September 1, 2022 | August 31, 2026 | CHEN, YA-WEN | reporter.nih.gov |
| Development and characterization of engineered therapeutic antibodies against SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,738,360 | August 1, 2021 | July 31, 2024 | AMARASINGHE, GAYA K. | reporter.nih.gov |
| Coronavirus Genome Replication | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,704,705 | March 15, 2021 | February 28, 2027 | CAMERON, CRAIG E. | reporter.nih.gov |
| Systems Immunogenetics of Biodefense and Emerging Pathogens in the Collaborative Cross | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $2,699,469 | September 1, 2020 | August 31, 2022 | BARIC, RALPH S | reporter.nih.gov |
| Serologic and Molecular Studies of human anti-hCoV antibody cross-immunity and protective responses among endemic HCoVs and SARS-CoV2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,655,001 | September 17, 2021 | August 31, 2025 | MARASCO, WAYNE A. | reporter.nih.gov |
| Function interactions between mitogen-activated protein kinases (MAPKs) and SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,563,708 | March 13, 2023 | February 29, 2028 | JOHNSON, JEFFREY R | reporter.nih.gov |
| Characterization of Persistent COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,560,715 | August 10, 2023 | July 31, 2027 | LI, JONATHAN | reporter.nih.gov |
| Targeting SARS-CoV-2 PLpro for COVID-19 treatment | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,558,532 | February 22, 2022 | January 31, 2027 | XIONG, RUI | reporter.nih.gov |
| The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,538,999 | September 17, 2021 | August 31, 2025 | KOBIE, JAMES J | reporter.nih.gov |
| A multipronged investigation of SARS-CoV-2 genome packaging | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,505,582 | April 16, 2022 | March 31, 2027 | SORANNO, ANDREA | reporter.nih.gov |
| Mechanisms of Gastrointestinal COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,503,469 | July 15, 2022 | June 30, 2027 | CIORBA, MATTHEW AARON | reporter.nih.gov |
| Wirelessly controlled BSL3 vivarium system for automated microdosing in studies of infectious diseases | NIH | Office of the Director, National Institutes of Health | 2021 to 2022 | $2,495,626 | August 1, 2021 | July 31, 2025 | HOANG, TUAN Q | reporter.nih.gov |
| Probing functioning lung at the cellular resolution in health and disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,475,000 | September 1, 2022 | August 31, 2027 | NIA, HADI TAVAKOLI | reporter.nih.gov |
| ACE2-targeted PET radiotracers for investigating spatiotemporal distribution of SARS-CoV-2 organ injury and therapy response. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,443,104 | September 17, 2021 | August 31, 2025 | WILSON, DAVID M | reporter.nih.gov |
| Role and Mitigation of Inflammasomes and Inflammation During COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,428,594 | July 15, 2022 | June 30, 2027 | TING, JENNY P | reporter.nih.gov |
| hHv1 channels in neutrophils and the innate immune inflammatory response | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,426,520 | August 5, 2022 | June 30, 2027 | GOLDSTEIN, STEVE A N | reporter.nih.gov |
| Overriding the Immune Evasion Tactics of Coronavirus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,422,685 | August 12, 2020 | July 31, 2025 | WARE, CARL F | reporter.nih.gov |
| Mechanisms of IgM mediated activation of the complement system | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,422,075 | June 2, 2021 | May 31, 2026 | GUTTMAN, MIKLOS | reporter.nih.gov |
| Alzheimer's Disease and Related Dementia-like Sequelae of SARS-CoV-2 Infection: Virus-Host Interactome, Neuropathobiology, and Drug Repurposing | NIH | National Institute on Aging | 2023 | $2,394,473 | May 15, 2023 | April 30, 2026 | CHENG, FEIXIONG | reporter.nih.gov |
| Covid 19 cytokine storm | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,371,605 | August 15, 2021 | July 31, 2025 | CHUGH, SUMANT SINGH | reporter.nih.gov |
| Host cellular network governing the development of post SARS-CoV-2 tissue sequelae | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,351,771 | February 14, 2020 | May 31, 2030 | SUN, JIE | reporter.nih.gov |
| Developing three-dimensional antisense oligonucleotide drugs against COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,341,581 | July 19, 2021 | June 30, 2026 | GUO, FENG | reporter.nih.gov |
| Host Defense Small Molecule Development for COVID-19 Treatment by Targeting Lysosome | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,330,378 | July 21, 2023 | June 30, 2027 | LIU, YUAN | reporter.nih.gov |
| Revising Anti-coronavirus Compounds to Enhance Activity and Optimize Delivery | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,268,282 | September 1, 2021 | August 31, 2024 | SCHOOLEY, ROBERT TURNER | reporter.nih.gov |
| Temporal Transcriptomics in Hospitalized COVID-19 Patients from Disparately Impacted Ancestral Groups for Therapeutic Discovery | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,263,760 | July 1, 2021 | June 30, 2025 | PERKINS, DOUGLAS JAY | reporter.nih.gov |
| Humoral Immune Mechanisms of Acute and Chronic Neurologic Sequelae of COVID-19 | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,260,647 | February 15, 2022 | November 30, 2025 | WILSON, MICHAEL R | reporter.nih.gov |
| Emergent Properties of Complex Systems: From Atoms to Macromolecules; from Humans to Societies | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,244,295 | June 1, 2017 | May 31, 2028 | LEVITT, MICHAEL | reporter.nih.gov |
| Defining the Translocation Mechanisms of SARS-CoV-2 nsp13 Helicase to Aid in Antiviral Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,229,089 | September 17, 2021 | August 31, 2027 | MCCULLAGH, MARTIN | reporter.nih.gov |
| Role of IRE1 Alpha in Coronavirus Infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,221,620 | March 11, 2022 | February 28, 2027 | FINK, SUSAN LEILANI | reporter.nih.gov |
| The Impact of SARS-CoV-2 Immune Dysregulation on Antifungal Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,207,883 | August 4, 2023 | July 31, 2027 | LEAL, SIXTO MANUEL | reporter.nih.gov |
| Mechanisms linking the plasminogen/fibrinogen axis to the pathogenesis of COVID-19 | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,206,716 | September 1, 2021 | July 31, 2025 | FLICK, MATTHEW J. | reporter.nih.gov |
| Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $2,205,056 | February 1, 2023 | January 31, 2028 | SPARKS, JEFFREY ANDREW | reporter.nih.gov |
| AI-based platform for predicting emerging vaccine-escape variants and designing mutation-proof antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,174,184 | May 6, 2022 | April 30, 2027 | WEI, GUOWEI | reporter.nih.gov |
| Mechanisms of lung and cardiac pathology in SARS-CoV-2 infections | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,168,424 | April 15, 2023 | January 31, 2027 | YOUNT, JACOB | reporter.nih.gov |
| Regulation of inflammatory gene expression during SARS2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,168,339 | February 18, 2022 | January 31, 2027 | MARAZZI, IVAN | reporter.nih.gov |
| Molecularly Engineered Lectins for Intranasal Prophylaxis and Treatment of Coronaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,156,579 | March 1, 2023 | February 29, 2028 | MARKOVITZ, DAVID MICHAEL | reporter.nih.gov |
| Immune, hormonal, and muscle mitochondrial determinants of recovery in Acute Respiratory Distress Syndrome survivors | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,151,841 | September 1, 2023 | July 31, 2028 | BALDWIN, MATTHEW R | reporter.nih.gov |
| Assessing the Impact of SARS-CoV-2 on Adipose Tissue Function and Glucose Homeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,139,449 | May 1, 2023 | April 30, 2028 | LO, JAMES C | reporter.nih.gov |
| mRNA-encoded Cas13 as a pan-respiratory antiviral | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,120,971 | January 23, 2023 | December 31, 2027 | SANTANGELO, PHILIP J | reporter.nih.gov |
| Cellular Mechanism of Oxysterol-Binding Protein (OSBP) in Viral Proliferation: A Chemical Biology Approach | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,088,096 | April 8, 2021 | March 31, 2027 | BURGETT, ANTHONY W.G. | reporter.nih.gov |
| Statistical Methods for Efficacy Trials of Vaccines and Monoclonal Antibodies Against Genetically-Diverse Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,067,031 | April 1, 2003 | June 30, 2029 | GILBERT, PETER B. | reporter.nih.gov |
| Uncover mechanisms underlying the development of chronic lung sequelae post COVID-19 | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,058,585 | August 1, 2023 | July 31, 2027 | SUN, JIE | reporter.nih.gov |
| Functional Role of HIF-PHDs in ARDS | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,051,945 | September 1, 2023 | August 31, 2027 | ELTZSCHIG, HOLGER K. | reporter.nih.gov |
| Development of an Oral Pan-Coronavirus Drug Cocktail | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,049,419 | July 7, 2023 | June 30, 2028 | POLYAK, STEPHEN J. | reporter.nih.gov |
| SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,048,861 | March 1, 2024 | February 28, 2027 | HUTCHINS, JEFF T | reporter.nih.gov |
| A New Small-Molecule Kinase Inhibitor for Airway Disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,038,199 | August 7, 2019 | June 30, 2027 | BROSCHAT, KAY O | reporter.nih.gov |
| The COVID-19 pandemic: Impact on mental health and HIV outcomes | NIH | National Institute of Mental Health | 2023 | $2,035,602 | March 20, 2023 | March 19, 2026 | ALTHOFF, KERI NICOLE | reporter.nih.gov |
| Preclinical development of an immunomodulatory agent capable of mitigating SARS-CoV-2 virus related hypercytokinemia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,000,000 | March 6, 2021 | February 29, 2024 | CRAIGO, JODI K | reporter.nih.gov |
| Phase 1/2a Clinical Study of Descartes-30 in Acute Respiratory Distress Syndrome | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,998,233 | May 1, 2021 | April 30, 2024 | STEWART, CHARLES ANDREW | reporter.nih.gov |
| High-throughput Imaging-integrated Vascular Model for Understanding Thromboembolism and Therapeutics Screening | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,993,722 | January 1, 2023 | November 30, 2026 | ZHANG, Y. SHRIKE | reporter.nih.gov |
| CMC of Peptide Formulation for the Treatment of ARDS | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,967,733 | June 1, 2022 | May 31, 2025 | CASTILLO, GERARDO M. | reporter.nih.gov |
| virtual compound screening using gene expression | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,911,280 | August 1, 2022 | May 31, 2027 | CHEN, BIN | reporter.nih.gov |
| SUPPLEMENTAL WORK-SARS-COV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,872,652 | April 1, 2019 | July 31, 2022 | KAYTOR, MICHAEL | reporter.nih.gov |
| A randomized controlled trial of smell training and trigeminal nerve stimulation in the treatment of COVID-related persistent smell loss | NIH | National Institute on Deafness and Other Communication Disorders | 2023 to 2025 | $1,869,850 | June 1, 2023 | May 31, 2028 | CORTESE, BERNADETTE | reporter.nih.gov |
| Activated Sugars, Oligosaccharides and Glycans for Antiviral Research | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $1,851,010 | June 1, 2021 | December 31, 2023 | AMINOVA, LEILA | reporter.nih.gov |
| Evaluating a Comprehensive Multimodal Outpatient Rehabilitation Program to Improve the Functioning of Persons Suffering from Post-acute Sequelae of SARS-CoV-2 infection (PASC): A Randomized Controlled | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $1,840,273 | April 12, 2023 | March 31, 2027 | DILLINGHAM, TIMOTHY R | reporter.nih.gov |
| Development of Medical Countermeasures for COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,824,494 | August 11, 2020 | September 30, 2022 | TAYLOR, RAYMOND | reporter.nih.gov |
| Structure-function of cytoprotective coagulation proteases and their receptors | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,792,500 | December 1, 2010 | March 31, 2025 | MOSNIER, LAURENT OLIVIER | reporter.nih.gov |
| Individualized Prediction of Treatment Effects Using Data from Both Embedded Clinical Trials and Electronic Health Records | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $1,791,807 | September 15, 2022 | July 31, 2025 | COOPER, GREGORY F. | reporter.nih.gov |
| Efficacy of Fenofibrate for COVID-19: A phase II randomized controlled trial | NIH | National Center for Advancing Translational Sciences | 2021 | $1,776,779 | January 1, 2021 | December 31, 2023 | CHIRINOS MEDINA, JULIO ALONSO | reporter.nih.gov |
| Development of multivalent, ultrapotent nanobody cocktails for SARS-CoV-2 neutralization | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,736,935 | February 9, 2022 | January 31, 2027 | SHI, YI | reporter.nih.gov |
| Quantitative high-throughput methods for antibody fragment optimization and discovery | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $1,710,520 | May 1, 2020 | July 31, 2023 | LAYTON, CURTIS | reporter.nih.gov |
| Neutrophil Heterogeneity and Immunopathogenesis of COVID-19 ARDS | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,705,089 | January 1, 2023 | December 31, 2027 | YAN, JUN | reporter.nih.gov |
| Coronavirus RNA synthesis by multicomponent protein machines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,689,898 | August 5, 2020 | July 31, 2026 | KIRCHDOERFER, ROBERT N | reporter.nih.gov |
| Role of Diabetes in MERS Coronavirus Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,660,135 | June 16, 2020 | May 31, 2024 | FRIEMAN, MATTHEW BRYAN | reporter.nih.gov |
| Next-generation alchemical free energy methods and quantum/machine-learning models for drug discovery | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,633,660 | August 1, 2015 | August 31, 2027 | YORK, DARRIN M | reporter.nih.gov |
| Impact of the COVID-19 pandemic, SARS-CoV-2 infection and social determinants of health on pregnancy complications, birth outcomes and post-pregnancy maternal cardiovascular and mortality outcomes | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $1,632,961 | April 1, 2022 | March 31, 2026 | MALEK, ANGELA M | reporter.nih.gov |
| Supplemental Citicoline Administration for Reduction of Lung Injury Efficacy Trial (SCARLET) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,614,003 | July 1, 2022 | March 31, 2026 | CROUSER, ELLIOTT D | reporter.nih.gov |
| Targeted treatment of acute lung injury using isolated lung perfusion | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,607,084 | December 20, 2023 | November 30, 2027 | KRON, IRVING L. | reporter.nih.gov |
| First-in-human study of two anti-SARS CoV-2 antibodies in health volunteers | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,571,599 | February 23, 2021 | June 30, 2023 | MONTANER, LUIS J | reporter.nih.gov |
| 1/2 WIN Ratio Analysis to Determine a Strategy of Non-Invasive SUpport for Respiratory Failure in the EmeRgency Department (WINDSURFER) | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,535,439 | September 15, 2025 | December 31, 2026 | WANG, HENRY E. | reporter.nih.gov |
| Software for sequencing human antibody proteins from polyclonal immune responses | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $1,527,557 | March 1, 2021 | February 28, 2025 | PATEL, ANAND | reporter.nih.gov |
| Constructing the nest - understanding the mechanisms of nidoviridae RNA genomes transcription and recombination | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $1,525,500 | September 14, 2022 | August 31, 2025 | ROUSKIN, SILVIA | reporter.nih.gov |
| A NOVEL STRATEGY TO INHIBIT SARS-COV-2 INFECTION AND COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,525,325 | June 13, 2024 | April 30, 2029 | GALLAY, PHILIPPE ANDRE | reporter.nih.gov |
| Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,521,312 | August 1, 2020 | July 31, 2026 | JUNG, MICHAEL E | reporter.nih.gov |
| Solvation directed drug design: from molecular physics to lead optimization | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,520,289 | July 15, 2022 | April 30, 2027 | KURTZMAN, THOMAS PHILIP | reporter.nih.gov |
| Computational design and development of small protein inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,520,056 | March 1, 2024 | January 31, 2029 | STRAUCH, EVA-MARIA | reporter.nih.gov |
| Impact of Heightened UPR Activation on Inflammasome Responses to Influenza and Secondary Streptococcus pneumoniae Infection in Aged Lung | NIH | National Institute on Aging | 2021 to 2022 | $1,491,600 | May 1, 2018 | April 30, 2024 | STOUT DELGADO, HEATHER WINONA | reporter.nih.gov |
| Structures and Dynamics of Proton and Cation-Dependent Channels and Transporters | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,474,187 | September 30, 2009 | June 30, 2025 | HONG, MEI | reporter.nih.gov |
| Emerging mechanisms of viral gene regulation from battles between host and SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,446,568 | August 1, 2023 | July 31, 2028 | LIU, CHANG | reporter.nih.gov |
| Rutgers Optimizes Innovation (ROI) Program | NIH | National Heart, Lung, and Blood Institute | 2021 | $1,443,599 | December 21, 2020 | November 30, 2023 | PANETTIERI, REYNOLD ALEXANDER | reporter.nih.gov |
| Metabolism-based interactions and organ-targeted delivery of molnupiravir, nirmatrelvir and remdesivir | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,440,524 | March 8, 2023 | February 29, 2028 | YAN, BINGFANG | reporter.nih.gov |
| The COVID-19 and Cancer Consortium (CCC19) Registry | NIH | National Cancer Institute | 2024 to 2025 | $1,433,332 | May 1, 2024 | April 30, 2029 | WARNER, JEREMY L | reporter.nih.gov |
| Mechanisms of a Novel Combined Immunodeficiency Caused by a Homozygous Mutation in COPG1 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,380,202 | May 3, 2018 | April 30, 2024 | GEHA, RAIF SALIM | reporter.nih.gov |
| An Integrated Host-Microbe Gene Classifier to Predict SARS-CoV-2 and Severe Disease in Children with Respiratory Viral Coinfections | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,362,012 | June 1, 2024 | February 28, 2029 | KENNEDY, JOSHUA | reporter.nih.gov |
| Molecular pathogenesis of COVID-19-associated coagulopathy and new therapeutic approaches | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,359,177 | January 1, 2024 | December 31, 2028 | AIOLFI, ROBERTO | reporter.nih.gov |
| A universal intranasal nanoengineered therapy against airborne RNA viruses | NIH | National Institute of Biomedical Imaging and Bioengineering | 2024 to 2025 | $1,328,784 | July 3, 2024 | April 30, 2028 | MAHAJAN, VINAY SUBHASH | reporter.nih.gov |
| Linking the conformational landscape to enzymatic function through functional site distant mutations | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,296,867 | January 1, 2022 | December 31, 2026 | SABO, THOMAS MICHAEL | reporter.nih.gov |
| Comprehensive profiling of SARS-CoV-2 antibody responses and escape pathways | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,292,062 | June 1, 2020 | March 31, 2022 | OVERBAUGH, JULIE M. | reporter.nih.gov |
| Immune dysregulation mechanisms of persistent post-COVID19 olfactory dysfunction | NIH | National Institute on Deafness and Other Communication Disorders | 2024 to 2025 | $1,287,704 | July 1, 2024 | June 30, 2029 | BANKOVA, LORA | reporter.nih.gov |
| Antibody repertoire characterization in the context of coronaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,283,747 | July 28, 2020 | May 31, 2023 | GEORGIEV, IVELIN | reporter.nih.gov |
| Multidimensional antibody engineering to enhance the potency and breadth of a betacoronavirus medical countermeasure | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,283,552 | July 1, 2023 | August 31, 2027 | BORNHOLDT, ZACHARY A | reporter.nih.gov |
| Mobile Health for Migrant Health (mHealth-4-Mhealth): Assessing the Effectiveness of Implementing an mHealth Program to Increase COVID-19 Testing and Treatment Among Rural Migrant Families | NIH | National Institute on Minority Health and Health Disparities | 2024 to 2025 | $1,273,499 | August 15, 2024 | October 31, 2028 | MCCULLOH, RUSSELL JAMES | reporter.nih.gov |
| Endotheliopathy and liver injury in COVID-19 | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,256,250 | August 11, 2021 | June 30, 2025 | IWAKIRI, YASUKO | reporter.nih.gov |
| SpongeBot: genetically engineered cells to suppress SARS-CoV-2 and future viruses | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $1,253,034 | December 19, 2020 | December 18, 2022 | IRVINE, DARRELL J | reporter.nih.gov |
| Interdisciplinary protein engineering approach to design high affinity antibodies for flaviviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,252,500 | November 15, 2018 | October 31, 2024 | FISER, ANDRAS | reporter.nih.gov |
| Comprehensive assessment of SARS-CoV-2-reactive antibodies in human milk to determine their potential as a COVID-19 therapeutic and as a means to prevent infection of breastfed babies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,241,023 | August 14, 2020 | July 31, 2024 | POWELL, REBECCA | reporter.nih.gov |
| Analyzing the potential for future bat coronavirus emergence in Myanmar, Laos, and Vietnam | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $1,230,594 | September 21, 2022 | May 15, 2024 | DASZAK, PETER | reporter.nih.gov |
| Mitochondrial metabolism controls alveolar epithelial cell fate | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,227,550 | September 1, 2024 | August 31, 2029 | HAN, SEUNGHYE | reporter.nih.gov |
| CEIRS - SARS-CoV-2 RESEARCH | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,209,203 | April 1, 2014 | May 20, 2022 | WEBBY, RICHARD | reporter.nih.gov |
| The Untranslated 3'End of SARS-CoV-2 RNA as a Determinant of Obesity-Accelerated Infectivity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,207,500 | September 14, 2021 | August 31, 2025 | FOX, PAUL L | reporter.nih.gov |
| NK cell mobilization as a pathogenic etiology of SARS-CoV-2 gastrointestinal disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,207,500 | August 1, 2021 | June 30, 2024 | REEVES, ROGER KEITH | reporter.nih.gov |
| Intestinal organoid modeling of SARS-CoV-2-stimulated innate and adaptive immunity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,180,625 | July 15, 2021 | June 30, 2024 | KUO, CALVIN J | reporter.nih.gov |
| Hepatotoxic mechanisms of anti-HIV- and anti-COVID-19 drugs and substance use disorders | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,175,625 | March 15, 2023 | January 31, 2028 | JI, CHENG | reporter.nih.gov |
| Real-time structural and functional studies of SARS-CoV-2 spike proteins | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,169,461 | September 20, 2023 | July 31, 2028 | LIN, YI-CHIH | reporter.nih.gov |
| Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoV | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,166,670 | August 9, 2017 | July 31, 2024 | BARIC, RALPH S | reporter.nih.gov |
| Pathobiological mechanisms of persistent post-COVID19 olfactory dysfunction | NIH | National Institute on Deafness and Other Communication Disorders | 2021 to 2022 | $1,164,667 | August 15, 2019 | June 30, 2024 | GOLDSTEIN, BRADLEY J | reporter.nih.gov |
| Mechanistic insights into multifaceted roles of coronavirus exoribonuclease complex | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,147,500 | August 1, 2023 | May 31, 2028 | YANG, YANG | reporter.nih.gov |
| Mechanistic Characterization of the IBD Risk Gene, PTPN2, as a Novel Susceptibility Marker for Increased SARS-CoV-2 Infection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,135,627 | August 1, 2021 | June 30, 2025 | MCCOLE, DECLAN | reporter.nih.gov |
| Developing a Novel E3 Ligase based Anti-inflammatory for ARDS | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,102,297 | February 1, 2022 | January 31, 2025 | MALLAMPALLI, RAMA K | reporter.nih.gov |
| 2/2 Self-directed mobile adaptive coping skills intervention to improve psychological distress symptoms among cardiorespiratory failure survivors: the Blueprint RCT | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,097,933 | February 15, 2024 | January 31, 2029 | MORRIS, CYNTHIA D | reporter.nih.gov |
| Inducible HMGB1 antagonist for viral-induced acute lung injury. | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $1,068,694 | August 16, 2023 | July 31, 2025 | BLANCO, JORGE C | reporter.nih.gov |
| Age related loss of immune resilience during response to severe respiratory viral infections | NIH | National Institute on Aging | 2024 to 2025 | $1,028,435 | July 1, 2024 | April 30, 2029 | SEGAL, LEOPOLDO NICOLAS | reporter.nih.gov |
| Development of IN-003PI as passive immunization against human metapneumovirus infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,013,468 | September 1, 2025 | July 31, 2028 | HUTCHINS, JEFF T | reporter.nih.gov |
| AT191: An inhaled & precision RNA therapeutic with pan-variant SARS-CoV-2 efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,004,473 | September 10, 2025 | August 31, 2028 | WEINBERGER, ARIEL | reporter.nih.gov |
| Covid-19 induced worsening of glomerular diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $994,136 | March 15, 2023 | December 31, 2027 | MACE, CAMILLE EMILIE ADELINE | reporter.nih.gov |
| The biochemical mechanism and pharmacological inhibition of phosphatidylinositol phosphate kinases | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $990,230 | August 15, 2023 | June 30, 2027 | HA, YA | reporter.nih.gov |
| Nitric Oxide Functionalized Antibiotics to Combat Infections and Thrombosis for Extracorporeal Life Support | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $983,782 | February 1, 2024 | January 31, 2028 | HANDA, HITESH | reporter.nih.gov |
| IN VITRO TESTING IN HUMAN CELL LINES FOR ANTIMICROBIAL ACTIVITY AGAINST SARS-COV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $971,739 | May 3, 2021 | May 2, 2022 | CHERRY, SARA | reporter.nih.gov |
| Role of ERK1/2 signaling in SARS-CoV-2 -induced dysregulated immunity and lung pathology. | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $930,578 | September 6, 2024 | June 30, 2029 | CHANNAPPANAVAR, RUDRAGOUDA | reporter.nih.gov |
| Comprehensive profiling of SARS-CoV-2 antibody responses and escape pathways | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $925,760 | June 1, 2020 | January 31, 2024 | OVERBAUGH, JULIE M. | reporter.nih.gov |
| Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $889,714 | January 1, 2022 | March 31, 2024 | ELLIS, DEBORAH A. | reporter.nih.gov |
| Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $866,473 | September 2, 2021 | June 30, 2026 | THARP, JEFFERY MICHEAL | reporter.nih.gov |
| Rapid antibody screening systems to identify and engineer antiviral protection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $849,771 | February 25, 2022 | January 31, 2025 | DEKOSKY, BRANDON JAMES | reporter.nih.gov |
| Repository of Monoclonal Antibodies (RoMA) against Hamster and Guinea Pig Proteins | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $835,137 | July 24, 2025 | June 30, 2030 | TORTORELLA, DOMENICO | reporter.nih.gov |
| Explore a key nucleotide synthesis enzyme to develop a broad-spectrum antiviral therapy. | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $831,235 | August 21, 2025 | July 31, 2030 | FENG, PINGHUI | reporter.nih.gov |
| Targeting Angiopoietin-like 4 (ANGPTL4) in Severe Community Acquired Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2025 | $827,909 | April 4, 2025 | January 31, 2029 | BHATRAJU, PAVAN KUMAR | reporter.nih.gov |
| 1/2 Self-directed mobile adaptive coping skills intervention to improve psychological distress symptoms among cardiorespiratory failure survivors: the Blueprint RCT | NIH | National Heart, Lung, and Blood Institute | 2024 | $820,823 | February 15, 2024 | January 31, 2025 | COX, CHRISTOPHER ETHAN | reporter.nih.gov |
| CEIRS - SARS-CoV-2 Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $808,808 | April 1, 2014 | July 31, 2022 | ORENSTEIN, WALTER A. | reporter.nih.gov |
| Implantable Bio-Artificial Pancreas (iBAP) | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $806,915 | September 26, 2017 | June 30, 2022 | ROY, SHUVO | reporter.nih.gov |
| 1/2 Self-directed mobile adaptive coping skills intervention to improve psychological distress symptoms among cardiorespiratory failure survivors: the Blueprint RCT | NIH | National Heart, Lung, and Blood Institute | 2025 | $796,582 | February 15, 2024 | January 31, 2029 | COX, CHRISTOPHER ETHAN | reporter.nih.gov |
| Regulation of inflammatory gene expression during SARS2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $794,868 | February 18, 2022 | October 3, 2022 | MARAZZI, IVAN | reporter.nih.gov |
| CGMP Compliant Closed Cell Culture System for culturing iPSC derived lung epithelial cells to COVID19 Therapy | NIH | National Institute of General Medical Sciences | 2021 | $773,076 | September 1, 2020 | August 31, 2022 | COLLINS, JOHN | reporter.nih.gov |
| Development of multivalent, ultrapotent nanobody cocktails for SARS-CoV-2 neutralization | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $769,010 | February 9, 2022 | February 18, 2022 | SHI, YI | reporter.nih.gov |
| Role and Mitigation of Inflammasomes and Inflammation During COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $768,215 | September 1, 2021 | June 30, 2022 | TING, JENNY P | reporter.nih.gov |
| Elucidating Olfactory Epithelial Anti-Viral Responses in Persistent Post-Viral Olfactory Dysfunction | NIH | National Institute on Deafness and Other Communication Disorders | 2022 to 2025 | $767,492 | February 1, 2022 | January 31, 2027 | YAN, CAROL H | reporter.nih.gov |
| Development of Sustained-Release Anti-coronavirus Nucleoside Phosphonate compounds | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $749,444 | February 21, 2017 | January 31, 2022 | SCHOOLEY, ROBERT TURNER | reporter.nih.gov |
| Role of Macrophages in CBD mediated attenuation of SEB-induced ARDS | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $746,874 | February 1, 2022 | July 31, 2026 | WILSON, KIESHA | reporter.nih.gov |
| Impact of Alcohol Misuse on Cognitive and Respiratory Outcomes in COVID-19-associated Acute Respiratory Failure | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $727,247 | September 22, 2021 | August 31, 2025 | BURNHAM, ELLEN L | reporter.nih.gov |
| Highly Selective Pathogen Inactivators For Treatment of Convalescent Transfusion Plasma | NIH | National Heart, Lung, and Blood Institute | 2021 | $717,598 | September 20, 2021 | August 31, 2023 | TABATADZE, DAVID R | reporter.nih.gov |
| Modulation of Acute Lung Injury by Type I Interferon Signaling | NIH | National Heart, Lung, and Blood Institute | 2025 | $690,626 | January 1, 2025 | November 30, 2028 | EMMER, BRIAN T | reporter.nih.gov |
| STRUCTURE-GUIDED RECEPTOR/INHIBITOR TRIMERIZATION AND RELATED STRATEGIES AGAINST CORONAVIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $686,255 | August 17, 2022 | July 31, 2024 | KE, AILONG | reporter.nih.gov |
| T cell modulation of COVID-19 disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $686,250 | September 20, 2021 | August 31, 2025 | MANESS, NICHOLAS JAMES | reporter.nih.gov |
| tRNA-derived RNA Fragments and their Role in Nasal SARS-CoV-2 Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $680,000 | July 1, 2022 | June 30, 2025 | BAO, XIAOYONG | reporter.nih.gov |
| The Impact of SARS-CoV-2 Immune Dysregulation on Antifungal Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $668,250 | August 5, 2022 | July 31, 2023 | LEAL, SIXTO MANUEL | reporter.nih.gov |
| CD38, T cells and post viral lung sequelae during aging | NIH | National Institute on Aging | 2025 | $639,740 | December 15, 2024 | November 30, 2029 | SUN, JIE | reporter.nih.gov |
| Pathogenic Mechanism and Therapeutic Approaches for Exercise Intolerance in Post-Acute Sequelae of COVID-19 | NIH | National Heart, Lung, and Blood Institute | 2025 | $633,045 | April 1, 2025 | January 31, 2029 | ZHANG, LIANGHUI | reporter.nih.gov |
| Immunomodulatory drug interventions for the prevention of host immune responses toward AAV-delivered anti-HIV antibodies | NIH | Office of the Director, National Institutes of Health | 2025 | $630,197 | February 1, 2025 | January 31, 2027 | FUCHS, SEBASTIAN PATRICK | reporter.nih.gov |
| Targeting polyamines to suppress SARS-CoV-2 related disease | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $613,994 | January 1, 2021 | April 30, 2023 | IGNATENKO, NATALIA A | reporter.nih.gov |
| Structure, Function and Antigenicity of Coronavirus Spike Proteins | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $613,032 | February 9, 2017 | January 31, 2023 | MCLELLAN, JASON SCOTT | reporter.nih.gov |
| Selectively Replicating Trojan Virus Vectors as Programmable CRISPR-Based Antiviral Therapies | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $612,000 | September 10, 2021 | August 31, 2024 | PHELPS, MICHAEL PAUL | reporter.nih.gov |
| Determining the ototoxic potential of COVID-19 therapeutics using machine learning and in vivo approaches | NIH | National Institute on Deafness and Other Communication Disorders | 2023 to 2024 | $606,378 | June 7, 2023 | November 30, 2024 | COFFIN, ALLISON B | reporter.nih.gov |
| Live Cell Fluorescent Assays for SARS-CoV-2 protease activity and COVID-19 Drug Discovery | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $600,000 | May 13, 2022 | October 31, 2024 | QUINN, ANNE MARIE | reporter.nih.gov |
| IND-Enabling Development of a Small Molecule COVID Therapeutic | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $600,000 | April 1, 2023 | March 31, 2026 | BENNETT, RYAN P | reporter.nih.gov |
| Affinity Reagents for the Immune System of Golden Hamster (for SARS-CoV-2 induced long-COVID disease) | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $600,000 | September 1, 2023 | August 31, 2025 | QI, HONG | reporter.nih.gov |
| Enabling risk-based testing through characterization of environmentally induced immune dysregulation and susceptibility to the SARS-CoV2 virus and COVID-19 | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $600,000 | August 13, 2014 | February 12, 2026 | BURLESON, FLORENCE | reporter.nih.gov |
| Development of Inhibitors Against SARS CoV-2 NSP16 Methyltransferase | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $599,970 | April 10, 2024 | March 31, 2027 | LI, HONGMIN | reporter.nih.gov |
| Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $599,788 | August 11, 2022 | July 31, 2025 | GOMPERTS, EDWARD | reporter.nih.gov |
| Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $598,928 | August 22, 2022 | July 31, 2025 | HARTY, RONALD N | reporter.nih.gov |
| A biophysical assay targeting SARS CoV-2 RNA | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $598,589 | June 27, 2022 | May 31, 2026 | STORY, SANDRA PAIGE | reporter.nih.gov |
| Drop-of-blood technology for diagnosis and therapeutic drug monitoring in patients with infectious disease | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2024 | $596,976 | July 15, 2022 | April 30, 2026 | KHISMATULLIN, DAMIR B | reporter.nih.gov |
| New target and new therapy for severe Covid-19 and viral hyperinflammation damage: renalase and renalase agonists | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $596,930 | September 7, 2023 | August 31, 2025 | BERKOWITZ, BARRY A | reporter.nih.gov |
| Targeting galectin-3 to intervene COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $596,637 | August 17, 2022 | July 31, 2025 | AHMED, HAFIZ | reporter.nih.gov |
| Targeting Covid-19 with a Therapeutic Interfering Particle | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $595,928 | April 5, 2021 | March 31, 2024 | ANDINO, RAUL | reporter.nih.gov |
| Acute Inhibition of TAK1 as a Means to Control COVID-19 Pulmonary Hyperinflammation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $593,995 | August 1, 2021 | May 31, 2024 | SCARNEO, SCOTT | reporter.nih.gov |
| A Novel Broad-spectrum Antiviral Agent | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $590,654 | January 1, 2021 | December 31, 2022 | MURAD, JOANA M | reporter.nih.gov |
| Inhibition of SARS-CoV-2 infection with a pan-coronavirus anti-viral peptide | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $588,038 | May 4, 2021 | August 31, 2022 | ROTOLO, JIM | reporter.nih.gov |
| RNA epigenetic modifications in SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $582,618 | February 1, 2025 | January 31, 2030 | LI, JIANRONG | reporter.nih.gov |
| Understanding the Risk of Bat Coronavirus Emergence | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $576,290 | June 1, 2014 | April 30, 2024 | DASZAK, PETER | reporter.nih.gov |
| Development and Evaluation of Radiotracers for PET Imaging Angiotensin-Converting Enzyme 2 (ACE2) | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $568,000 | July 15, 2021 | April 30, 2026 | YUE, XUYI | reporter.nih.gov |
| Affinity Reagents and Sensor Platform Development for Blood Biochemical Monitoring | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2024 | $549,024 | April 1, 2022 | December 31, 2024 | PAN, JING | reporter.nih.gov |
| Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung Injury | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $544,376 | February 10, 2017 | January 31, 2023 | VOGEL, STEFANIE N. | reporter.nih.gov |
| Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $537,069 | August 5, 2023 | July 31, 2028 | HOCHBERG, CHAD | reporter.nih.gov |
| Targeting the VHR phosphatase for the treatment of sepsis in COVID-19 patients | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $536,250 | April 6, 2021 | September 30, 2023 | TAUTZ, LUTZ | reporter.nih.gov |
| Increasing the Success of ARDS Therapeutic Clinical Trials: Novel Trial Design and Targeting of the P-selectin Pathway | NIH | National Heart, Lung, and Blood Institute | 2022 | $529,354 | September 19, 2022 | August 31, 2024 | BIME, CHRISTIAN | reporter.nih.gov |
| Developing dynamic prognostic and risk-stratification models for informing prescribing decisions in older adults with Coronavirus Disease 2019 | NIH | National Institute on Aging | 2021 | $524,715 | May 1, 2019 | April 30, 2023 | LIN, JOSHUA K | reporter.nih.gov |
| Structure of the SARS-CoV-2 Nucleocapsid: building block to viral capsid | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $515,577 | July 5, 2023 | June 30, 2025 | SAPHIRE, ERICA OLLMANN | reporter.nih.gov |
| Necroptosis in SARS-CoV-2 pathogenesis, evolution, and therapy | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $513,000 | February 1, 2022 | January 31, 2024 | BALACHANDRAN, SIDDHARTH | reporter.nih.gov |
| RNA homodimerization strand displacement pathways to extended duplexes: Atomistic details for a mechanistic paradigm to identify unique antiviral targets for current and emerging viral pandemics | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $507,121 | August 21, 2025 | July 31, 2028 | EVANSECK, JEFFREY D | reporter.nih.gov |
| Mechanisms of Thrombosis in SARS CoV-2 Infection | NIH | National Heart, Lung, and Blood Institute | 2025 | $503,637 | January 15, 2025 | November 30, 2028 | WOOD, JEREMY P | reporter.nih.gov |
| Development of Broad Coronavirus Immunity Targeting the Fusion Peptide | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $503,332 | June 9, 2021 | May 31, 2023 | KULP, DANIEL | reporter.nih.gov |
| Midcareer Investigator Award in Patient-Oriented Research in the Microbiome and Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $500,124 | May 1, 2022 | April 30, 2027 | DICKSON, ROBERT PICKETT | reporter.nih.gov |
| Novel animal models to study organ-specific SARS-CoV-2-induced pathology | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $499,125 | November 11, 2022 | October 31, 2025 | TUMANOV, ALEXEI V | reporter.nih.gov |
| Developing Lectins as Inhibitors of Coronavirus Spike Proteins | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $498,000 | September 1, 2022 | May 31, 2027 | GUSEMAN, ALEX JOSEPH | reporter.nih.gov |
| Evaluation of Artemisia as an Effective Combination Therapy Against SARS-CoV-2 Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $489,609 | May 20, 2022 | April 30, 2025 | KELLOGG, JOSHUA | reporter.nih.gov |
| Host inflammatory response to SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $485,375 | September 1, 2021 | August 31, 2024 | GALE, MICHAEL | reporter.nih.gov |
| Innate and adaptive defenses against SARS-COV-2 in the oral cavity during acute unvaccinated and breakthrough infections | NIH | National Institute of Dental & Craniofacial Research | 2022 | $483,000 | September 1, 2022 | August 31, 2024 | WEINBERG, AARON | reporter.nih.gov |
| Developing broad-based treatments for respiratory viruses by targeting host cell TTSPs | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $477,146 | March 20, 2024 | February 28, 2026 | WHITTAKER, GARY R | reporter.nih.gov |
| Loss of A-to-I editing stimulates SARS-CoV-2 anti-viral responses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $475,750 | May 1, 2022 | April 30, 2025 | AUNE, THOMAS M. | reporter.nih.gov |
| Functional characterization of SARS-CoV-2 myeloid cell receptors as an immunopathogenic mechanisms of COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $466,125 | July 2, 2021 | June 30, 2023 | WANG, JUN | reporter.nih.gov |
| Multi-dimensional comparison of differentially pathogenic coronaviruses (CoV) in human lung tissue | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $465,000 | September 24, 2021 | August 31, 2023 | LIM, JEAN KYOU | reporter.nih.gov |
| An L-Aptamer-Displacement Assay for High-Throughput Screening of RNA-Targeted Small Molecule Antivirals | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $463,775 | September 1, 2023 | August 31, 2025 | SCZEPANSKI, JONATHAN THOMAS | reporter.nih.gov |
| Comparison of RAS inhibitor classes for cerebrovascular management in hypertensive patients who contracted COVID-19 infection | NIH | National Institute on Aging | 2021 | $462,000 | May 15, 2021 | April 30, 2023 | SALAT, DAVID H | reporter.nih.gov |
| Entry inhibition of SARS-CoV-2 by human LRRC15 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $459,688 | July 12, 2023 | June 30, 2025 | LEE, SANGHYUN | reporter.nih.gov |
| Central IRB Services for DCR/NIAID COVID-19 Clinical Trials | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $459,294 | March 30, 2020 | March 29, 2021 | SEGAL RAIM, SHARON | reporter.nih.gov |
| Small molecule inhibitors targeting the SARS-CoV-2 pathogenicity factor Nsp1 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $458,408 | June 7, 2022 | May 31, 2024 | STECKELBERG, ANNA-LENA | reporter.nih.gov |
| Digital pathology for defining myeloid cell-mediated lung injury during acute SARS CoV-2 Infection in hamsters | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $453,750 | September 8, 2022 | August 31, 2025 | MARTINOT, AMANDA | reporter.nih.gov |
| Mitoquinone/mitoquinol mesylate as oral and safe Postexposure Prophylaxis for Covid-19 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $451,000 | July 14, 2023 | June 30, 2026 | KELESIDIS, THEODOROS | reporter.nih.gov |
| Metabolic Energy Crisis Signature Predicts Quality of Life in Survivors of Acute Respiratory Failure | NIH | National Institute of Nursing Research | 2021 to 2022 | $450,471 | May 1, 2021 | April 30, 2024 | LANGLEY, RAYMOND JULIAN | reporter.nih.gov |
| Profiling the immune response to convalescent plasma therapy during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $450,313 | April 13, 2022 | September 6, 2024 | BREAM, JAY H. | reporter.nih.gov |
| Notch regulation of airway epithelial-immune cell cross-talk in SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $448,688 | July 9, 2025 | June 30, 2027 | DESHMUKH, UMESH S | reporter.nih.gov |
| Roles of human surfactant collectin variants in the susceptibility of COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $448,250 | July 8, 2022 | June 30, 2025 | WANG, GUIRONG | reporter.nih.gov |
| Leveraging Pathogen-Host Networks to Identify Virus-specific and Estradiol-regulated Mechanisms during Respiratory Infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $447,935 | June 9, 2023 | May 31, 2026 | SHOEMAKER, JASON EDWARD | reporter.nih.gov |
| Molecular Mechanism of Folding of Nsp12 and Assembly of the SARS-CoV-2 RNA Polymerase Complex by the Cytosolic Chaperonin CCT | NIH | National Institute of General Medical Sciences | 2024 | $447,548 | September 18, 2024 | August 31, 2027 | WILLARDSON, BARRY M | reporter.nih.gov |
| Thymidine Phosphorylase: a Novel Target of Antiplatelet Therapy | NIH | National Heart, Lung, and Blood Institute | 2022 | $444,000 | January 3, 2019 | June 30, 2025 | LI, WEI | reporter.nih.gov |
| Identifying existing, FDA-approved drugs with clinically protective effects against coronavirus disease 2019 using a big data approach | NIH | National Library of Medicine | 2021 to 2022 | $442,834 | April 20, 2021 | March 31, 2024 | LAMBERT, JOSH | reporter.nih.gov |
| PET imaging of viral infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $442,750 | July 1, 2021 | June 30, 2025 | LEE, ZHENGHONG | reporter.nih.gov |
| GS-441524 is Pharmacodynamically Equivalent to Remdesivir and Pharmacokinetically Superior Drug for the Treatment of COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $442,002 | January 1, 2021 | December 31, 2023 | LI, CHUN | reporter.nih.gov |
| Mechanisms of exacerbation of COVID-19 pathogenesis in mice expressing human ACE2 by polycyclic aromatic hydrocarbons (PAHs), and its protection by inhibition of soluble epoxide hydrolase (sEH) | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $441,315 | February 1, 2021 | January 31, 2024 | MOORTHY, BHAGAVATULA | reporter.nih.gov |
| Effects of SARS-CoV-2 Antiviral Ribonucleoside Analogues on Mitochondrial DNA | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $440,900 | January 27, 2022 | December 31, 2024 | PICKRELL, ALICIA M | reporter.nih.gov |
| Alcohol and the alveolar epithelial barrier | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $440,375 | February 1, 2017 | January 31, 2023 | KOVAL, MICHAEL H. | reporter.nih.gov |
| Novel small-molecule inhibitors of SARS-CoV-2 protease | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $440,000 | December 1, 2020 | November 30, 2023 | SONG, YONGCHENG | reporter.nih.gov |
| Molecular principles of anti-COVID-19 drug uptake by human nucleoside transporters | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $439,732 | September 12, 2022 | August 31, 2024 | LEE, SEOK-YONG | reporter.nih.gov |
| Immune evasion by SARS-CoV-2: the role of HLA class I | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $439,725 | November 17, 2022 | October 31, 2024 | BOUVIER, MARLENE | reporter.nih.gov |
| Development of MMP14-laden exosomes as a novel anti-SARS-CoV-2 therapy | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $439,725 | January 1, 2023 | December 31, 2025 | HAN, KYUYEON | reporter.nih.gov |
| Assessing the Risk of SARS-CoV-2 Remdesivir Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $439,500 | July 1, 2021 | June 30, 2023 | HULTQUIST, JUDD F | reporter.nih.gov |
| Elucidating the role of SERINC5 in SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $438,625 | May 18, 2022 | April 30, 2025 | STAVROU, SPYRIDON | reporter.nih.gov |
| Creation and Validation of cell-based screening systems for SARS-CoV-2 drug targets | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $438,625 | May 6, 2022 | April 30, 2025 | MELENDY, THOMAS | reporter.nih.gov |
| Determining the role of 90K on SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $437,895 | July 14, 2025 | June 30, 2027 | STAVROU, SPYRIDON | reporter.nih.gov |
| De Novo Designed Protein Nanoparticle Agonists Targeting the Tie2 Receptor for the Treatment of ARDS and Sepsis in Patients with COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $436,804 | August 1, 2021 | December 31, 2023 | UEDA, GEORGE | reporter.nih.gov |
| Therapy for long-COVID in a preclinical model | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $433,125 | July 11, 2024 | May 31, 2027 | KAUFMAN, DANIEL | reporter.nih.gov |
| Covalent inhibitors of host cell entry by SARS-CoV-2 for treatment of COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $432,850 | April 20, 2022 | March 31, 2025 | BOGYO, MATTHEW | reporter.nih.gov |
| Multi-pronged therapy for immune system regeneration and recovery in a FIP model of MIS-C | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $432,010 | August 15, 2021 | July 31, 2024 | KOL, AMIR | reporter.nih.gov |
| Live-cell imaging of SARS-CoV-2 replication organelle formation and RNA synthesis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $431,350 | September 15, 2023 | August 31, 2025 | AMBROSE, ZANDREA | reporter.nih.gov |
| Programming designer DNA nanostructures for blocking enveloped viral infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $431,298 | July 14, 2023 | June 30, 2025 | HUANG, WEISHAN | reporter.nih.gov |
| Novel treatment for respiratory distress due to SARS-CoV2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $430,188 | June 11, 2021 | May 31, 2023 | GRIENDLING, KATHY K | reporter.nih.gov |
| SELF-MASKED ALDEHYDES AS INHIBITORS OF THE CYSTEINE PROTEASES 3CL PROTEASE, CATHEPSIN L, AND CRUZAIN | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $430,103 | November 4, 2021 | October 31, 2024 | MEEK, THOMAS | reporter.nih.gov |
| A general, virus-free platform to rapidly map SARS-CoV-2 drug resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $429,243 | July 1, 2021 | June 30, 2024 | CHOUDHARY, AMIT | reporter.nih.gov |
| Synergistic Interactions of SARs-CoV2 and environmental toxicants in Experimental Parkinsonism | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $429,000 | July 1, 2021 | December 31, 2022 | SMEYNE, RICHARD J | reporter.nih.gov |
| Modifying Remdesivir Prodrug Design to Enhance the Active Metabolite Accumulation in the Lung (Resubmission) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $429,000 | May 13, 2022 | April 30, 2024 | ZHU, HAOJIE | reporter.nih.gov |
| Targeting Grainyhead-Like 2 Suppresses Entry Factors of SARS-CoV-2 in Epithelial Cells of Oral Mucosa. | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2023 | $429,000 | April 1, 2022 | March 31, 2026 | CHEN, WEI | reporter.nih.gov |
| Targeting SARS-CoV-2 RNA Pseudoknots Using Triplex-Forming Peptide Nucleic Acids | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $428,330 | November 1, 2021 | October 31, 2024 | ROZNERS, ERIKS | reporter.nih.gov |
| Chitin and chitinases in SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $427,834 | June 1, 2023 | May 31, 2025 | VAN DYKEN, STEVEN | reporter.nih.gov |
| COVID-19 comorbidity studies in Syrian hamster models | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $427,625 | July 15, 2021 | June 30, 2023 | KAWAOKA, YOSHIHIRO | reporter.nih.gov |
| A Novel Cell-based System for the Search of SARS-CoV-2 ORF3a Inhibitors against COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $427,625 | June 21, 2024 | April 30, 2027 | ZHAO, RICHARD YUQI | reporter.nih.gov |
| Bi-substrate Inhibitors of SARS-CoV-2 Nsp14 Methyltransferase | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $426,250 | June 15, 2022 | May 31, 2025 | CHEN, LIQIANG | reporter.nih.gov |
| Glycopolymer Inhibitors of Heparan Sulfate Proteoglycan Binding Pathogens | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $426,000 | April 1, 2016 | August 31, 2025 | MCREYNOLDS, KATHERINE D | reporter.nih.gov |
| Seeing the Unseen: High-Throughput Prospective Profiling and inhibition of SARS-CoV-2 receptor-binding domain variants | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $424,911 | December 8, 2022 | November 30, 2025 | KHARE, SAGAR D | reporter.nih.gov |
| Multi-target suppression of pro-inflammatory cytokines using engineered targeted ribonucleases | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $424,875 | July 15, 2021 | July 14, 2023 | WILSON, GERALD M. | reporter.nih.gov |
| Development and Evaluation of Novel Aptamer-based Therapeutics Targeting SARS-CoV-2 in a Physiologically-Relevant Model of Human Airway Epithelium | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $424,875 | July 12, 2021 | June 30, 2024 | DESTEFANO, JEFFREY J | reporter.nih.gov |
| Targeting macrophages to reduce the combined injury effects of radiation and virus exposure | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $423,500 | May 5, 2022 | April 30, 2024 | MARPLES, BRIAN | reporter.nih.gov |
| Transcriptional regulation of ACE2 and the adaption of SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $423,500 | November 11, 2022 | October 31, 2025 | ZHU, YIPING | reporter.nih.gov |
| TMPRSS2 as a potential target for treatments of COVID-19 and respiratory infectious viruses in lung | NIH | National Heart, Lung, and Blood Institute | 2021 | $421,219 | September 20, 2021 | December 31, 2021 | CHEN, YA-WEN | reporter.nih.gov |
| Targeting the neuropilin-1 receptor (NRP-1)/VEGF-A axis for neuropathic pain | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $419,470 | September 1, 2021 | August 31, 2023 | KHANNA, RAJESH | reporter.nih.gov |
| Trimerization of the N-terminal Domain of ACE2 for Bifunctional Trapping of Future SARS-CoV-2 Variants | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $419,300 | July 9, 2021 | June 30, 2024 | LIU, RIHE | reporter.nih.gov |
| Targeting SARS-CoV-2 induced lung immunopathology using novel genetic mouse models | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $419,072 | May 9, 2022 | April 30, 2025 | TUMANOV, ALEXEI V | reporter.nih.gov |
| Blocking TMPRSS2 expression for prevention of SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $415,250 | July 12, 2021 | June 30, 2025 | CAI, HOUJIAN | reporter.nih.gov |
| Probing in situ higher order structures of monoclonal antibodies at water-air and water-oil interfaces via high-field nuclear magnetic resonance spectroscopy for viral infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $414,331 | August 17, 2023 | July 31, 2026 | MOHAMMADIGOUSHKI, HADI | reporter.nih.gov |
| NON-CANONICAL MECHANISMS FOR INTERFERON-LAMBDA REGULATION OF SARS-COV-2 INFECTION | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $412,533 | September 1, 2023 | August 31, 2025 | HEMANN, EMILY ANN | reporter.nih.gov |
| A synthetic miR-7702: a potential therapeutic approach for SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $411,400 | July 10, 2025 | June 30, 2027 | LIU, LIN | reporter.nih.gov |
| Development of fluorogenic and chemiluminogenic main protease substrates for cellular and in vivo imaging of SARS-CoV-2 | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2023 | $411,152 | May 1, 2022 | February 28, 2025 | LIU, WENSHE RAY | reporter.nih.gov |
| Translational Regulation of SARS-CoV-2 in response to viral S protein-induced signaling | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $408,375 | August 14, 2023 | July 31, 2025 | MAZUMDER, BARSANJIT | reporter.nih.gov |
| Administrative Supplement to R21: Mechanism and in vivo activity of novel glycan-based therapy against flavivirus endothelial permeability and vascular leak | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $407,743 | March 1, 2020 | February 28, 2023 | HARRIS, EVA | reporter.nih.gov |
| Supplement to "New ACE2 activator and its prodrug as novel therapeutic regents for inflammatory pulmonary diseases" | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $406,756 | April 2, 2020 | December 31, 2022 | JIA, HONGPENG | reporter.nih.gov |
| Extracellular vesicles encapsulating CRISPR machinery for treatment of SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $406,194 | January 19, 2023 | December 31, 2025 | CAI, HOUJIAN | reporter.nih.gov |
| The Development of Reversible Covalent PROTAC Technology as a New Anti-COVID-19 Strategy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $405,679 | June 25, 2021 | May 31, 2024 | XU, SHIQING | reporter.nih.gov |
| Development of PROTACs Targeting Papain-like Protease as Broad-Spectrum Anti-Coronavirus Therapeutics | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $405,450 | May 26, 2022 | April 30, 2025 | XU, SHIQING | reporter.nih.gov |
| Modeling early SARS-CoV-2 pathogenesis in human lung organoids and slice cultures | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $404,450 | February 1, 2022 | March 31, 2024 | RUSTAGI, ARJUN | reporter.nih.gov |
| Tissue Factor's Role in the Pathogenesis of Hypercoagulability in COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $404,250 | March 1, 2022 | February 28, 2026 | LELLA, VIJAYA MOHAN RAO | reporter.nih.gov |
| Understanding how the MERS Coronavirus protein ORF4b interactions with importin alpha modulate innate immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $404,113 | July 1, 2021 | June 30, 2023 | BASLER, CHRISTOPHER F | reporter.nih.gov |
| Dissecting mechanisms of antibody-Fc interactions that shape innate immune antiviral responses. | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $399,221 | November 17, 2023 | October 31, 2026 | GUNN, BRONWYN MEI | reporter.nih.gov |
| Engineering Immunity for Broad Protection Against Betacoronaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $399,168 | July 1, 2024 | June 30, 2028 | MILLER, EMILY HAPPY | reporter.nih.gov |
| Full-length sequencing of individual RNAs from heterogeneous samples | NIH | National Human Genome Research Institute | 2022 | $398,040 | March 15, 2022 | August 31, 2023 | AGNEW, WILLIAM S | reporter.nih.gov |
| Design and evaluation of a multivalent nanobody construct for prevention or treatment of SARS-CoV-2 | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $397,382 | September 1, 2021 | August 31, 2023 | CHAMPION, JULIE | reporter.nih.gov |
| A deep learning-enhanced multiphysics and multiscale framework for predictive modeling of inflammation-induced thrombosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $393,117 | February 1, 2024 | January 31, 2027 | LI, HE | reporter.nih.gov |
| Investigating fibrinogen as a pathologic and targetable mediator of COVID-19-associated coagulopathy | NIH | National Heart, Lung, and Blood Institute | 2025 | $391,250 | March 1, 2025 | February 29, 2028 | MAIER, CHERYL | reporter.nih.gov |
| Elucidating the impact of immune imprinting on SARS-CoV-2 variant vaccination strategies using a humanized mouse model | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $387,288 | August 15, 2024 | July 31, 2029 | BOWEN, ANTHONY | reporter.nih.gov |
| Development of a platform to non-invasively assess microvascular endothelial dysfunction at the bedside in COVID-19 patients throughout intensive care. | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $385,726 | July 1, 2021 | June 30, 2024 | BUSCH, DAVID RICHARD | reporter.nih.gov |
| Novel Nasal Formulations Containing EC16 for Minimizing COVID-19-Associated Anosmia | NIH | National Institute on Deafness and Other Communication Disorders | 2022 | $384,971 | July 1, 2022 | October 31, 2024 | HSU, STEPHEN | reporter.nih.gov |
| Development of an accessible Cognitive Behavioral Therapy digital therapeutic for individuals with Long COVID | NIH | National Institute of Nursing Research | 2025 | $383,159 | September 16, 2025 | August 30, 2026 | RANDA, LAURA | reporter.nih.gov |
| An antioxidant enzyme to suppress hyperinflammation induced by SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $380,317 | August 19, 2022 | July 31, 2024 | WEN, JING | reporter.nih.gov |
| Structures and Dynamics of Proton- and Cation-Conducting Viroporins | NIH | National Institute of General Medical Sciences | 2025 | $378,680 | September 30, 2009 | August 31, 2029 | HONG, MEI | reporter.nih.gov |
| Next-generation Lasers for Enabling Ultrafast Functional Pulmonary MRI | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $378,602 | September 1, 2024 | June 30, 2027 | CHEKMENEV, EDUARD | reporter.nih.gov |
| PPE Request | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $373,601 | February 5, 2021 | January 31, 2022 | KESLER, KAREN | reporter.nih.gov |
| Targeting CD14: A Novel Therapeutic Approach for Acute Respiratory Distress Syndrome | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $372,816 | September 1, 2024 | August 31, 2029 | MABREY, FRANCES LINZEE | reporter.nih.gov |
| Modeling early SARS-CoV-2 pathogenesis in human lung organoids and slice cultures | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $368,019 | February 1, 2022 | June 30, 2026 | RUSTAGI, ARJUN | reporter.nih.gov |
| Induction of Broad Sarbecovirus Immunity Via A Vaccine Engineered From SARS-CoV-2 Heptad Repeat 1 | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $363,528 | May 28, 2024 | April 30, 2029 | STAMPFER, SAMUEL DAVID | reporter.nih.gov |
| Oral Antivirals against COVID-19 and Clinical Outcomes in High Risk Populations | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $347,188 | July 12, 2023 | June 30, 2025 | BUTT, ADEEL A | reporter.nih.gov |
| Host-microbe interactions and SARS-CoV-2 susceptibility and symptoms in a novel human challenge model | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $347,000 | July 19, 2023 | February 28, 2025 | KELLY, MATTHEW SCOTT | reporter.nih.gov |
| Brain ACE2 in Alzheimer's disease in relation to COVID-19 | NIH | National Institute on Aging | 2021 to 2022 | $341,600 | September 1, 2021 | May 31, 2024 | SUZUKI, YUICHIRO JUSTIN | reporter.nih.gov |
| Structural Studies of the Coronavirus Life Cycle | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $341,219 | May 21, 2020 | November 30, 2022 | KIRCHDOERFER, ROBERT N | reporter.nih.gov |
| SCD-PICC Therapy for Respiratory Insufficiency associated with COVID-19 in non-ICU settings | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $331,757 | August 15, 2022 | August 14, 2023 | PINO, CHRISTOPHER | reporter.nih.gov |
| Extracorporeal SuPAR Extraction to Prevent COVID-19-associated Acute Kidney Injury | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $326,710 | September 20, 2021 | February 28, 2023 | HAYEK, SALIM | reporter.nih.gov |
| Characterizing neurocognitive deficits in post-acute sequelae of COVID-19 | NIH | National Institute on Aging | 2025 | $325,672 | September 16, 2025 | May 31, 2027 | MEGHDADI, AMIR HOSSEIN | reporter.nih.gov |
| Role of increased circulating microparticles in adverse outcomes of COVID-19 patients with diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 | $324,720 | April 1, 2022 | March 31, 2024 | HE, PINGNIAN | reporter.nih.gov |
| K23 Resubmission - Impact of adoptive T cell therapy on immunity to SARS-CoV-2 after bone marrow transplant | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $321,036 | August 15, 2024 | July 31, 2029 | CONWAY, SUSAN | reporter.nih.gov |
| Repurposing Incyclinide for the Treatment of Hospitalized COVID-19 Patients | NIH | National Center for Advancing Translational Sciences | 2021 | $315,000 | March 1, 2021 | August 31, 2023 | SCADUTO, JOSEPH | reporter.nih.gov |
| A PTP4A3 inhibitor for SARS-CoV-2-mediated acute lung injury | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $313,708 | July 15, 2022 | August 31, 2022 | LAZO, JOHN S. | reporter.nih.gov |
| Protective film-forming disinfectant based on chitosan/water/ethanol tertiary solutions | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $311,321 | July 13, 2022 | February 28, 2023 | VERTEGEL, ALEXEY A | reporter.nih.gov |
| Development of a Neutrophil Degranulation Inhibitor to Treat ARDS | NIH | National Heart, Lung, and Blood Institute | 2023 | $306,424 | April 1, 2023 | December 31, 2024 | MCLEISH, KENNETH R | reporter.nih.gov |
| Discovery of broad-spectrum, cross-neutralizing bispecific antibodies against SARS-CoV-2 using high throughput functional screening | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $300,000 | February 1, 2021 | May 31, 2022 | WU, GEORGE GUIKAI | reporter.nih.gov |
| Novel Peptide Fusion Inhibitors for the Treatment of COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $300,000 | August 23, 2022 | July 31, 2025 | TARRAN, ROBERT | reporter.nih.gov |
| Treatment of Inflammatory Complications of Viral Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $300,000 | June 20, 2022 | August 6, 2023 | AGRAWAL, ANDY | reporter.nih.gov |
| Antibodies in the neurologic effects of COVID-19 | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $300,000 | September 6, 2024 | August 31, 2025 | AL-HARTHI, LENA | reporter.nih.gov |
| Multiplexed CRISPR-based immune cell RNA profiling by flow and mass cytometry | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $299,978 | December 1, 2020 | November 30, 2022 | O'CONNELL, MITCHELL | reporter.nih.gov |
| Lung delivery of novel ACE2 variants for COVID-19 | NIH | National Heart, Lung, and Blood Institute | 2022 | $299,842 | September 1, 2022 | February 29, 2024 | HENKIN, JACK | reporter.nih.gov |
| Development of a Novel Resolvin-Based Therapy for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $299,561 | August 6, 2021 | January 31, 2023 | SCIAVOLINO, FRANK | reporter.nih.gov |
| SCH: A structural causal framework for adaptive experiments | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $299,422 | August 6, 2025 | July 31, 2029 | SANTACATTERINA, MICHELE | reporter.nih.gov |
| Targeting inflammation and oxidative stress to treat acute lung injury with CNP-miR146a | NIH | National Heart, Lung, and Blood Institute | 2022 | $299,271 | April 1, 2022 | March 31, 2023 | JACKSON, DAVID | reporter.nih.gov |
| mRNA Delivery of a Panel of Single-Domain Antibodies for Combinatorial Deciphering of Therapeutic Targets for Covid-19 Related Cytokine Release Syndrome | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $299,128 | February 1, 2022 | October 31, 2023 | GAO, XIANG | reporter.nih.gov |
| Niclosamide Formulations for the Treatment of Influenza Infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $298,479 | July 8, 2022 | June 30, 2023 | FUJII, GARY | reporter.nih.gov |
| The effects of immunosuppression on SARS-CoV-2 persistence, virus genetic diversity and clinical outcomes of COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $296,625 | July 9, 2024 | May 31, 2026 | SALVATORE, MIRELLA | reporter.nih.gov |
| Development of a CO2-bicarbonate combined membrane capture system for accessible treatment of acute respiratory failure. | NIH | National Heart, Lung, and Blood Institute | 2021 | $293,121 | September 17, 2021 | May 31, 2022 | CHANG, BRIAN YALE | reporter.nih.gov |
| mTOR Regulation of Basal Antiviral Immunity in the Elderly | NIH | National Institute on Aging | 2021 | $292,388 | May 15, 2019 | February 16, 2022 | MANNICK, JOAN B | reporter.nih.gov |
| Novel Stimulation to Improve Respiratory Function in ARDS and Severe COVID-19 Patients | NIH | National Heart, Lung, and Blood Institute | 2022 | $275,405 | June 1, 2022 | May 31, 2024 | HARDIN, BILL | reporter.nih.gov |
| New mechanism-based TREM-1 therapy for acute respiratory distress syndrome | NIH | National Heart, Lung, and Blood Institute | 2023 | $272,741 | August 1, 2023 | October 31, 2024 | SIGALOV, ALEXANDER B | reporter.nih.gov |
| Understanding the Molecular Basis of Translation Inhibition by SARS-CoV-2 NSP14 and its Role in SARS-CoV-2 Immune Evasion | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $265,529 | May 22, 2023 | April 30, 2026 | HSU, CHUN CHIEH | reporter.nih.gov |
| The Development of CSD peptides for the therapeutic treatment of post-acute sequelae of COVID-19 (PACS) | NIH | National Heart, Lung, and Blood Institute | 2023 | $259,332 | September 15, 2023 | July 31, 2024 | MACKENZIE, BREANNE | reporter.nih.gov |
| Transient Gene Therapy as Broad Spectrum Antiviral | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $255,932 | September 1, 2021 | September 30, 2022 | BOGUNOVIC, DUSAN | reporter.nih.gov |
| Automation of Liquid Nitrogen Freezer for Cryopreservation of Unique Human Biospecimens at the Vanderbilt Biospecimen Storage Facility | NIH | Office of the Director, National Institutes of Health | 2023 | $252,800 | August 1, 2023 | July 31, 2024 | BICK, ALEXANDER | reporter.nih.gov |
| PERK determines polarized targeting of growth factors in neurons | NIH | National Institute on Aging | 2021 | $250,948 | February 15, 2020 | January 31, 2024 | GIDALEVITZ, TALI | reporter.nih.gov |
| First-in-class small molecules that enhance lung barrier function during acute respiratory distress syndrome (ARDS) as potential therapeutics for COVID-19 | NIH | National Heart, Lung, and Blood Institute | 2021 | $249,998 | July 1, 2021 | December 31, 2023 | AUSUBEL, FREDERICK M | reporter.nih.gov |
| Targeted mRNA therapies treating ARDS | NIH | National Heart, Lung, and Blood Institute | 2025 | $249,000 | August 16, 2025 | July 31, 2028 | ZHOU, ZHENGJIE | reporter.nih.gov |
| Comprehensive analysis of epistasis in drug resistance potential of Mpro from SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $243,713 | February 1, 2025 | January 31, 2027 | BOLON, DANIEL N | reporter.nih.gov |
| Discovery of Novel Anti-inflammatory, Non-immunosuppressive Molecules forMitigation of Cytokine Storm in COVID-19 Patients | NIH | National Heart, Lung, and Blood Institute | 2022 | $236,387 | May 1, 2022 | December 31, 2023 | MOGHADDAM, MEHRAN F | reporter.nih.gov |
| Role of Endothelial eNAMPT Secretion and TLR4 Signaling in the ARDS Vascular Endotype | NIH | National Heart, Lung, and Blood Institute | 2022 | $232,675 | May 20, 2022 | August 30, 2022 | GARCIA, JOE G. N. | reporter.nih.gov |
| Unlocking the Potential of HIV-Infected Deceased Donors for Organ Transplantation | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $231,886 | December 1, 2015 | November 30, 2022 | TOBIAN, AARON A | reporter.nih.gov |
| Brief Acceptance and Commitment Therapy for HIV-Infected At-Risk Drinkers Administrative Supplement | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $229,857 | March 15, 2018 | February 28, 2022 | WOOLF-KING, SARAH E | reporter.nih.gov |
| Targeted mRNA therapies treating ARDS | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $221,246 | August 1, 2023 | July 31, 2025 | ZHOU, ZHENGJIE | reporter.nih.gov |
| Identifying Genetic Regulators and New Models of Wild Type Coronavirus Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $194,375 | June 2, 2020 | May 31, 2023 | GRALINSKI, LISA | reporter.nih.gov |
| Integrated Cognitive Rehabilitation and Cognitive Behavioral Therapy Intervention for patients with Post-COVID-19 Cognitive Impairment and Depression | NIH | National Institute of Mental Health | 2025 | $194,157 | December 1, 2024 | November 30, 2029 | BECKER, JACQUELINE HELCER | reporter.nih.gov |
| Broad Spectrum Anti-viral Compounds Targeting the SKI Complex | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $193,125 | June 5, 2020 | May 31, 2023 | FRIEMAN, MATTHEW BRYAN | reporter.nih.gov |
| Applying a Targeted Machine Learning and Causal Inference Approach to Analyzing Long-Term Sequelae of COVID-19 Infection Through the National COVID Cohort Collaborative. | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $190,688 | September 4, 2024 | May 31, 2026 | BUTZIN-DOZIER, ZACHARY | reporter.nih.gov |
| Accelerating discovery of neutralizing paratopes with Functional Antibody Screening Technology | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $189,375 | January 24, 2020 | December 31, 2023 | HAN, ARUM | reporter.nih.gov |
| Leveraging the sensitivity of antigen-specific T cells to interrogate disease mechanisms and identify therapeutic targets for Long COVID | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $175,428 | August 1, 2025 | July 31, 2027 | PAINTER, MARK M | reporter.nih.gov |
| Physiologic Predictors of Respiratory Failure in Patients Presenting with Dyspnea | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $172,792 | July 1, 2023 | June 30, 2025 | MCGUIRE, WILLIAM CAMERON | reporter.nih.gov |
| Temporal trends in quality indicators of palliative care for patients with chronic illness hospitalized with acute respiratory failure | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $172,692 | May 1, 2023 | July 8, 2025 | NOMITCH, JAMIE TREADWAY | reporter.nih.gov |
| The effects of immunosuppression on SARS-CoV-2 persistence, virus genetic diversity and clinical outcomes of COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $169,500 | April 2, 2025 | May 31, 2027 | SALVATORE, MIRELLA | reporter.nih.gov |
| Structure-guided design of protease-resistant, lipopeptide inhibitors of SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $168,136 | March 1, 2023 | June 24, 2025 | KUHN, ARIEL JADE | reporter.nih.gov |
| MLL1 drives collaborative leukocyte-endothelial cell signaling and thrombosis after coronavirus infection | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $165,184 | September 29, 2023 | September 28, 2025 | PARCHMENT, NATHANIEL | reporter.nih.gov |
| Role of macrophages in CBD mediated attenuation of SEB-induced ARDS | NIH | National Institute of General Medical Sciences | 2022 to 2023 | $162,501 | February 1, 2022 | August 7, 2023 | WILSON, KIESHA | reporter.nih.gov |
| Teratogenicity assessment of new antiviral drugs using 3D morphogenesis models | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 | $156,500 | August 10, 2023 | July 31, 2025 | MARIKAWA, YUSUKE | reporter.nih.gov |
| Web Based Therapist Training on Complicated Grief Therapy | NIH | National Institute of Mental Health | 2021 | $156,130 | March 1, 2019 | February 28, 2021 | KOBAK, KENNETH A | reporter.nih.gov |
| PHOX2B Congenital Central Hypoventilation Syndrome (CCHS) Physiologic Signatures in Readiness for Future Clinical Trials | NIH | National Center for Advancing Translational Sciences | 2022 to 2023 | $155,000 | July 1, 2022 | June 30, 2024 | WEESE-MAYER, DEBRA ELLYN | reporter.nih.gov |
| Targeting polyamines to suppress SARS-CoV-2 related disease | NIH | National Center for Advancing Translational Sciences | 2023 | $153,040 | January 1, 2021 | April 30, 2024 | IGNATENKO, NATALIA A | reporter.nih.gov |
| Developing Lectins as Inhibitors of Coronavirus Spike Proteins | NIH | National Institute of General Medical Sciences | 2022 to 2023 | $152,084 | September 1, 2022 | January 31, 2024 | GUSEMAN, ALEX JOSEPH | reporter.nih.gov |
| Mechanism of pulmonary vascular wall thickening in COVID-19 | NIH | National Institute on Aging | 2021 to 2022 | $150,800 | September 1, 2021 | June 30, 2024 | SUZUKI, YUICHIRO JUSTIN | reporter.nih.gov |
| The Use of Human Cardiac Organoids to Model COVID-19 Cytokine Storm Induced Cardiac Injury | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $150,527 | May 1, 2022 | April 30, 2025 | ARHONTOULIS, DIMITRIOS CHRISOVALANTOU | reporter.nih.gov |
| MiRNA-based Therapeutics for SARS-CoV-2 S1 mediated neuroinflammation and beta-amyloid production | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $149,500 | May 1, 2022 | April 30, 2025 | MARKOUTSA, ELENI | reporter.nih.gov |
| A Mixed Methods Evaluation of the Implementation of Prone Positioning in COVID-19 ARDS | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $142,426 | September 3, 2021 | June 30, 2023 | HOCHBERG, CHAD | reporter.nih.gov |
| Double-stranded RNA dictates SARS-CoV-2 nucleocapsid condensation temperature | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $137,986 | July 18, 2023 | July 31, 2024 | RODEN, CHRISTINE ANNE | reporter.nih.gov |
| Biomarkers and subphenotypes predictive of clinical outcomes in patients with COVID-19 related acute respiratory distress syndrome | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $129,294 | January 1, 2023 | June 30, 2024 | ALIPANAH-LECHNER, NARGES | reporter.nih.gov |
| Functional and antigenic evolution of SARS-related coronaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $128,574 | June 10, 2022 | May 31, 2023 | STARR, TYLER NELSON | reporter.nih.gov |
| Decoding Viral Control of Host Kinase Signaling to Design Combination Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $125,010 | August 12, 2022 | February 15, 2023 | BOUHADDOU, MEHDI | reporter.nih.gov |
| COVID-19: NIAID SPECIMEN REPOSITORY | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $117,253 | September 30, 2014 | September 29, 2021 | PHIPPARD, DEBORAH | reporter.nih.gov |
| Antibody display libraries for precision screening of antibody immune responses to SARS-CoV-2 | NIH | Office of the Director, National Institutes of Health | 2022 | $117,244 | May 9, 2022 | August 31, 2023 | DEKOSKY, BRANDON JAMES | reporter.nih.gov |
| Validation of a Genetic-based Biomarker Panel for Stratification of Mortality Risk in ARDS Patients | NIH | National Heart, Lung, and Blood Institute | 2023 | $115,125 | April 1, 2023 | March 31, 2025 | BIME, CHRISTIAN | reporter.nih.gov |
| Characterization of the SARS-CoV-2-mediated piracy of p38ß | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $98,512 | November 22, 2023 | November 21, 2025 | HIGGINS, CHRISTINA | reporter.nih.gov |
| Defining Mechanisms of SARS-CoV-2 Entry Inhibitors in the Respiratory Epithelium | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $98,512 | August 1, 2024 | July 31, 2027 | ACUNA, JORGE ALBERTO | reporter.nih.gov |
| Optimization of a broad and potent decoy receptor for SARS-associated viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $95,981 | April 1, 2021 | November 30, 2022 | CHAN, KUI KIU | reporter.nih.gov |
| Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents | NIH | National Institute of General Medical Sciences | 2021 | $95,215 | September 2, 2021 | August 31, 2022 | THARP, JEFFERY MICHEAL | reporter.nih.gov |
| Abnormal gene splicing in neuropathic pain - Supplement | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $91,505 | July 1, 2021 | January 2, 2022 | LOPEZ SOTO, EDUARDO JAVIER | reporter.nih.gov |
| Understanding spillover potential of European and African bat sarbecoviruses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $87,970 | January 1, 2023 | December 31, 2024 | ZEPEDA, SAMANTHA KATHLEEN | reporter.nih.gov |
| Exploring the Potential of Natural Products to Combat COVID-19 | NIH | National Center for Complementary & Integrative Health | 2022 to 2023 | $82,420 | April 1, 2022 | October 31, 2023 | RISENER, CAITLIN JAIME | reporter.nih.gov |
| Rational structure-guided design of broadly reactive next-generation therapeutics to treat non-communicable snakebite in Africa | NIH | Fogarty International Center | 2021 | $79,560 | August 10, 2019 | May 31, 2022 | WIBMER, CONSTANTINOS KURT | reporter.nih.gov |
| Targeting metabolic pathways in lung injury | NIH | National Heart, Lung, and Blood Institute | 2022 | $79,294 | September 15, 2022 | September 14, 2023 | SHENDEROV, KEVIN | reporter.nih.gov |
| Developing a Biomimetic Lactating Mammary Lobe for Therapeutic Safety | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $78,040 | April 1, 2025 | July 31, 2027 | LEE, AMY H | reporter.nih.gov |
| What does it really mean to be broad? Uncovering underlying biology behind broadly neutralizing antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $78,040 | September 15, 2025 | September 14, 2028 | LYSKI, ZOE | reporter.nih.gov |
| "Investigation of Membrane Fusion Interactions of Enveloped Viruses using Magnetically-Labeled Liposomes" | NIH | National Institute of General Medical Sciences | 2022 | $76,946 | June 1, 2022 | October 23, 2023 | SANTRA, SANTIMUKUL | reporter.nih.gov |
| SMAC Mimetics as Broad-Spectrum Antivirals | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $75,520 | September 15, 2025 | November 14, 2026 | DUGGAN, NATASHA NOTANDO | reporter.nih.gov |
| Cystatin F expression on microglia is critical for constraining demyelination following viral infection of the central nervous system | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $75,052 | September 1, 2025 | August 31, 2027 | MURRAY, KAITLIN | reporter.nih.gov |
| In situ structures of SARS-CoV-2 Spike fusion intermediates and Spike-antibody-Fc receptor complexes | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $73,894 | January 1, 2024 | August 31, 2025 | GRUNST, MICHAEL WILLIAM | reporter.nih.gov |
| A new therapeutic approach against kidney damage in LN and COVID-19 | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2023 | $69,174 | March 4, 2022 | April 28, 2023 | VILLANUEVA, VERONICA | reporter.nih.gov |
| Probing the ribosome-dependent mechanisms of human alphacoronavirus Nsp1 | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $68,494 | September 1, 2024 | August 31, 2026 | BALAJI, SHRAVANI | reporter.nih.gov |
| ACR Basic and Clinical Research Conference: Rheumatologic Complications of Emerging Viral Infections / SARS-CoV-2 | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $54,000 | August 10, 2021 | July 31, 2022 | KUHN, KRISTINE A. | reporter.nih.gov |
| Multidisciplinary studies on overcoming SARS-CoV-2 main protease drug resistance and on fitness costs | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $48,974 | May 1, 2025 | February 6, 2028 | NEILSEN, GRACE | reporter.nih.gov |
| Targeting SARS-CoV-2 PLpro for COVID-19 treatment | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $41,147 | February 22, 2022 | March 31, 2022 | XIONG, RUI | reporter.nih.gov |
| The Pathogenic Role of IL-33 in the SARS-CoV-2-Infected Lung | NIH | National Heart, Lung, and Blood Institute | 2025 | $38,922 | March 1, 2026 | February 28, 2028 | FLEMING, CLAIRE | reporter.nih.gov |
| Studies on the SARS-CoV-2 Main Protease Dimerization Mechanism | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $38,674 | December 1, 2024 | November 30, 2025 | DELGADO, RENEE | reporter.nih.gov |
| Understanding Ribosomal Dependent Virulence Pathways Employed by Non-Structural Protein 1 in Emerging Human Beta-Coronaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $37,058 | September 1, 2025 | August 31, 2028 | VETICK, MICHAEL | reporter.nih.gov |
| Software for sequencing human antibody proteins from polyclonal immune responses | NIH | National Institute of General Medical Sciences | 2021 | $23,935 | March 1, 2021 | May 10, 2021 | PATEL, ANAND | reporter.nih.gov |
| Novel Approaches Against Emerging Antimicrobial Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $11,000 | February 1, 2022 | January 31, 2023 | JARVIS, THALE CROSS | reporter.nih.gov |
| 2023 2023 Nucleosides, Nucleotides and Oligonucleotides GRC & GRS | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $7,000 | February 10, 2023 | July 30, 2023 | SELEY-RADTKE, KATHERINE L | reporter.nih.gov |
| Viral Infection and Inflammation Workshop 2024 | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $7,000 | July 17, 2024 | June 30, 2025 | KURITZKES, DANIEL R. | reporter.nih.gov |
| RespiDART 2022: Frontiers in Drug Development against Respiratory Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $6,500 | December 1, 2022 | November 30, 2023 | SCHINAZI, RAYMOND FELIX | reporter.nih.gov |
| Understanding how the MERS Coronavirus protein ORF4b interactions with importin alpha modulate innate immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $5,392 | July 1, 2021 | November 15, 2021 | BASLER, CHRISTOPHER F | reporter.nih.gov |
| RespiDART & Emerging Viruses: Frontiers in Drug Development against Respiratory Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $5,000 | December 16, 2020 | November 30, 2021 | SCHINAZI, RAYMOND FELIX | reporter.nih.gov |
| Respi-DART: Frontiers in drug development against respiratory viruses and emerging viruses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $5,000 | November 18, 2024 | October 31, 2025 | SCHINAZI, RAYMOND FELIX | reporter.nih.gov |
| Identifying existing, FDA-approved drugs with clinically protective effects against coronavirus disease 2019 using a big data approach | NIH | National Library of Medicine | 2021 | $1 | April 1, 2021 | April 2, 2021 | SANDHU, HARPAL SINGH | reporter.nih.gov |
| COVID-FIS: A PHASE 2 PLACEBO-CONTROLLED PILOT STUDY IN COVID-19 OF FISETIN TO ALLEVIATE DYSFUNCTION AND EXCESSIVE INFLAMMATORY RESPONSE IN OLDER ADULTS IN NURSING HOMES | NIH | National Institute on Aging | 2024 | $1 | September 15, 2020 | November 30, 2024 | PIGNOLO, ROBERT JOHN | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Research Triangle Institute | Research Triangle Park, NC | 1 | $965.8 million | 0 | $0 |
| Technical Resources International, Inc. | Bethesda, MD | 2 | $150.1 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 1 | $89.8 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 7 | $25 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 6 | $22.9 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 5 | $20.3 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 8 | $19.8 million | 0 | $0 |
| Washington University | Saint Louis, MO | 7 | $18.3 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 4 | $16.4 million | 0 | $0 |
| University of Washington | Seattle, WA | 11 | $16 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 9 | $15.5 million | 0 | $0 |
| Feinstein Institute for Medical Research | Manhasset, NY | 1 | $15 million | 0 | $0 |
| Stanford University | Stanford, CA | 7 | $14.5 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 8 | $13.3 million | 0 | $0 |
| Baruch S. Blumberg Institute | Doylestown, PA | 1 | $12.5 million | 0 | $0 |
| Brown University | Providence, RI | 3 | $12.4 million | 0 | $0 |
| Aligos Therapeutics, Inc. | South San Francisco, CA | 1 | $11.3 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 9 | $11 million | 0 | $0 |
| Emory University | Atlanta, GA | 13 | $10.7 million | 0 | $0 |
| Foundation for the Nih | North Bethesda, MD | 1 | $10.2 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 7 | $9.9 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 6 | $8.6 million | 0 | $0 |
| Duke University | Durham, NC | 8 | $8.2 million | 0 | $0 |
| Ohio State University | Columbus, OH | 6 | $7.4 million | 0 | $0 |
| George Mason University | Fairfax, VA | 1 | $7.4 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 7 | $7.2 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 5 | $6.7 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 7 | $6.6 million | 0 | $0 |
| Rockefeller University | New York, NY | 2 | $6.3 million | 0 | $0 |
| University of Louisville | Louisville, KY | 4 | $6 million | 0 | $0 |
| Georgia State University | Atlanta, GA | 3 | $5.9 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 2 | $5.4 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 3 | $5.4 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 8 | $5.3 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 6 | $5.2 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 5 | $5.1 million | 0 | $0 |
| Vxbiosciences, Inc. | Oakland, CA | 1 | $4.8 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 4 | $4.8 million | 0 | $0 |
| University of Texas at Austin | Austin, TX | 3 | $4.7 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 3 | $4.7 million | 0 | $0 |
| Deloitte Consulting, LLP | Arlington, VA | 1 | $4.3 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 7 | $4.3 million | 0 | $0 |
| Sound Pharmaceuticals, Inc. | Seattle, WA | 1 | $4.2 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 4 | $4.1 million | 0 | $0 |
| Michigan State University | East Lansing, MI | 2 | $4.1 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 3 | $3.9 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 4 | $3.9 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 2 | $3.8 million | 0 | $0 |
| Nubad, LLC | Greer, SC | 2 | $3.8 million | 0 | $0 |
| Rush University Medical Center | Chicago, IL | 4 | $3.7 million | 0 | $0 |
| Tufts University Boston | Boston, MA | 2 | $3.7 million | 0 | $0 |
| Medical University of South Carolina | Charleston, SC | 3 | $3.7 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 2 | $3.6 million | 0 | $0 |
| Oklahoma State University | Stillwater, OK | 3 | $3.6 million | 0 | $0 |
| University of Chicago | Chicago, IL | 2 | $3.4 million | 0 | $0 |
| Rensselaer Polytechnic Institute | Troy, NY | 1 | $3.3 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 5 | $3.3 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 4 | $3.2 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 3 | $3.1 million | 0 | $0 |
| Keck Graduate Inst of Applied Life Scis | Claremont, CA | 1 | $3.1 million | 0 | $0 |
| Purdue University | West Lafayette, IN | 1 | $3.1 million | 0 | $0 |
| Inhalon Biopharma, Inc. | Morrisville, NC | 2 | $3.1 million | 0 | $0 |
| Venatorx Pharmaceuticals, Inc. | Malvern, PA | 1 | $3 million | 0 | $0 |
| Kansas State University | Manhattan, KS | 1 | $3 million | 0 | $0 |
| Sanford Burnham Prebys Medical Discovery Institute | La Jolla, CA | 2 | $3 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 1 | $2.8 million | 0 | $0 |
| Applied Biomedical Science Institute | San Diego, CA | 1 | $2.8 million | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 1 | $2.7 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 4 | $2.6 million | 0 | $0 |
| Yale University | New Haven, CT | 6 | $2.5 million | 0 | $0 |
| Fluid Synchrony, LLC | Pasadena, CA | 1 | $2.5 million | 0 | $0 |
| Trustees of Boston University | Boston, MA | 1 | $2.5 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 3 | $2.4 million | 0 | $0 |
| University of New Mexico Health Scis CTR | Albuquerque, NM | 1 | $2.3 million | 0 | $0 |
| University of Georgia Research Foundation Inc | Athens, GA | 4 | $2.2 million | 0 | $0 |
| University of Oklahoma HLTH Sciences CTR | Oklahoma City, OK | 1 | $2.1 million | 0 | $0 |
| Wistar Institute | Philadelphia, PA | 2 | $2.1 million | 0 | $0 |
| Rutgers University New Brunswick | New Brunswick, NJ | 2 | $2.1 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 1 | $2.1 million | 0 | $0 |
| Nupeak Therapeutics, Inc. | Saint Louis, MO | 1 | $2 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 3 | $2 million | 0 | $0 |
| Cytoagents, Inc. | Pittsburgh, PA | 1 | $2 million | 0 | $0 |
| Cartesian Therapeutics, Inc. | Gaithersburg, MD | 1 | $2 million | 0 | $0 |
| Pharmain Corporation | Bothell, WA | 1 | $2 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 2 | $1.9 million | 0 | $0 |
| Texas A&M University | College Station, TX | 5 | $1.9 million | 0 | $0 |
| Humanetics Corporation | Edina, MN | 1 | $1.9 million | 0 | $0 |
| Midwest Bioprocessing Center, LLC | Peoria, IL | 1 | $1.9 million | 0 | $0 |
| Biocryst Pharmaceuticals, Inc. | Durham, NC | 1 | $1.8 million | 0 | $0 |
| Ecohealth Alliance, Inc. | New York, NY | 2 | $1.8 million | 0 | $0 |
| Protillion Biosciences, Inc. | Burlingame, CA | 1 | $1.7 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 2 | $1.7 million | 0 | $0 |
| Washington State University | Pullman, WA | 3 | $1.6 million | 0 | $0 |
| Abterra Biosciences, Inc. | San Diego, CA | 1 | $1.5 million | 0 | $0 |
| Harvard Medical School | Boston, MA | 1 | $1.5 million | 0 | $0 |
| Herbert H. Lehman College | New York, NY | 1 | $1.5 million | 0 | $0 |
| Rutgers Biomedical/health Sciences-Rbhs | New Brunswick, NJ | 1 | $1.4 million | 0 | $0 |
| Rhode Island Hospital | Providence, RI | 1 | $1.4 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 1 | $1.4 million | 0 | $0 |
| Arkansas Children's Hospital Res Inst | Little Rock, AR | 1 | $1.4 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 174 | $132,791,927 | 0 | $0 |
| 2024 | 184 | $398,799,956 | 0 | $0 |
| 2023 | 221 | $600,129,868 | 0 | $0 |
| 2022 | 211 | $424,380,630 | 0 | $0 |
| 2021 | 178 | $254,415,513 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed) | PA-24-194 | NIH | May 7, 2027 | Not listed | Notice number printed on 1 award here | |
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 1 award here | |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 232 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 232 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 232 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 232 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 232 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 232 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 232 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 232 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 232 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 232 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 232 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 232 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 232 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 232 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 232 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 232 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 232 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 232 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.